The Role of MKK3 in Mediating Signals to the p38 MAP Kinase Pathway: A Dissertation by Wysk, Mark Allen
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2000-11-08 
The Role of MKK3 in Mediating Signals to the p38 MAP Kinase 
Pathway: A Dissertation 
Mark Allen Wysk 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, Chemical Actions and 
Uses Commons, and the Enzymes and Coenzymes Commons 
Repository Citation 
Wysk MA. (2000). The Role of MKK3 in Mediating Signals to the p38 MAP Kinase Pathway: A 
Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/mk2q-1b09. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/184 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
THE ROLE OF MKK3 IN MEDIATING SIGNALING TO THE p38 MAP KINASE
PATHWAY
A DISSERTATION PRESENTED
MARK ALLEN WYSK
Submitted to the Faculty of the
University of Massachusetts Graduate School of Biomedical Sciences, Worcester
In partial fulfilment of the requirement for the degree of:
DOCTOR OF PHILOSOPHY
November 8, 2000
Department of Biochemistry and Molecular Biology
Kendall Knight, Ph.D., Chair of Committee
Reid Gilmore, Ph.D., Member of Committee
Anthony Carruthers, Ph.D., Member of Committee
William Theurkauf, Ph.D., Member of Committee
John Blenis, Ph.D., Member of Committee
iii
DEDICATION
This dissertation is dedicated to the loving memory of my mother, Beatrice
(Stearns) Wysk without whom this dissertation would not have been possible.
I also wish to acknowledge other members of my family here especially. my
brother (and best friend) Steve his wife Laurie and my nieces and nephews:
Scott, Eric Krysta and Loran. My sister Judy her husband Carlo and their family
(including six nieces, one nephew 13 grand-nieces and grand-nephews, one
great-grand-niece and one great-grand-nephew) and of course Aunt Mary. Your
loving support kept me going all these years.
ACKNOWLEDGMENTS
During my time in graduate school I have encountered many people and made
many friends, too many in fact to fully mention here. Nonetheless, there are a
few people I do wish to acknowledge.
. First and foremost I gratefully acknowledge my mentor, Roger Davis , for his
encouragement and support during the course of my thesis research.
I would like to thank all members of Roger Davis ' lab , past and present with
special thanks to the following: Drs. Zoya Galcheva-Gargova and Laxman
Gangwani for your friendship, patience and understanding. I wish to thank Dr.
Perry Hall for scientific correspondence and patiently listening to me complain
about grad school. To my former roommate and bench-mate Jeff Rogers for
friendship, sushi , trips to O'Connors and for keeping me sane. Thanks to Victor
Lazaron , Benoit Derijard and Martin Dickens , for just being friends. Thanks to all
past and present members of the Peterson , Doxsey, Stephenson , Czech
Corvera , Ip, Theurkauf , and Lambright labs (did I forget anybody?) for many
scientific converstions and great TGIF's. Finally, I wish to thank all the graduate
students for the many good times we have shared (you know who you are).
ACKNOWLEDGMENT
The data presented in this Dissertation was generated in collaboration with
Hong-Tao Lu, Ph. D. , Howard Hughes Medical Institute and Section of
Immunobiology, Vale University School of Medicine. I gratefully acknowledge
Hong-Tao s contributions to the material presented in chapters three and four of
this thesis.
Portions of this dissertation appear in the following publications:
Wysk, M. , and Davis , R.J. Structure and regulation of the murine mkk3 gene.
Implications for muscle-specific expression of MKK3b. (2000) (Manuscript in
preparation)
Wysk, M. , Vang, D. , Lu, T.* , Flavell , R.A. , and Davis , R.J. (1999)
Requirement of mitogen-activated protein kinase kinse 3 (MKK3) for tumor
necrosis factor- induced cytokine expression. Proc. Natl Acad Sci USA, 96
7:3763-8 1999
Lu, H. T.* , Yang, D. D.* , Wysk, M. , Gatti , E. , Mellman , I. , Davis , R. J. , and
Flavell , R. A. (1999) Defective IL- 12 production in mitogen-activated protein
(MAP) kinase 3 (mkk3)-deficient mice. EMBO , 18, 7: 1845-57 1999
Equally contributed
The work presented in this Dissertation also contributed to the followingpublications: 
Otterbein , L.E. , Bach , F. H., Alam , J. , Soares, M. , Tao- , H. , Wysk, M. , Davis
R.J. , Flavell , R.A, and Choi, AM. (2000) Carbon monoxide has anti-
inflammatory effects involving the mitogen -activated protein kinase pathway.
Nat. Med. 6: 422-428
Constant, S. L.* , Dong, C* , Vang, D. , Wysk, M. , Davis, R.J. , and Flavell , R.A
(2000) JNK1 is required for T-cell mediated immunity against Lei$mania major
infection. Journal of Immunology
Yang, D. D.* , Wysk, M. , Tournier, C.* , Lu T, Xu, J. , Davis , R.J. , and Flavell,
R.A (1997) Targeted disruption of the mkk4 gene causes embryonic death
inhibition of JNK activation and defects in AP- 1 transcription activity. Proc. Natl.
Acad. Sci. USA 94:3004-3009
Dong, C.*, Yang, D. D.* , Wysk, M. , Whitmarsh , A.J., Davis, R.J. , and Flavell
R.A (1997) Defective T-Cell differentiation in the absence of JNK1. Science
282: 2092-2095
Taglienti , C. , Wysk, M. , and Davis , R.J. (1996) Molecular cloning of the
epidermal growth factor-stimulated protein kinase p56-KKIAMRE. Oncogene 13
(12): 2563-2574
, L. , Wysk, M. , Gonzalez, F. , and Davis , R.J. (1994) Genomic loci of human
mitogen-activated protein kinases. Oncogene 9(2): 647-649
Equally contributed
VUL
ABSTRACT
p38 mitogen-activated protein (MAP) kinases represent a subgroup of MAP
kinases that respond to environmental stress and inflammatory cytokines. p38
MAPK is activated by two upstream kinases MKK3 and MKK6, by dual
phosphorylation on threonine and tyrosine in conserved kinase subdomain VII.
Until recently the relative roles of MKK3 and MKK6 have remained unclear. I
have undertaken two strategies in an effort to understand the importance of
MKK3 as a p38 MAPK activator. First, I cloned and characterized the murine
mkk3 gene and determined the structure of the 5 terminus. Comparison of the
murine and human mkk3 genes revealed that the mouse gene encodes a single
MKK3 isoform, MKK3b, and the human gene encodes two isoforms , MKK3a and
MKK3b. Comparison of the mouse and human mkk3 genes suggests that
expression of MKK3a and MKK3b is regulated from different promotors. Analysis
of the mkk3 promoter demonstrates that muscle specific expression of murine
MKK3b is controlled, in part, by the transcription factors MEF2 and MyoD.
Second, I have utilized a gene targeting strategy to disrupt the murine mkk3 gene
and to examine the effect on p38 MAPK signaling. I found that there is a p38-
specific signaling defect in MKK3 deficient primary mouse embryo fibroblasts
(MEF) which correlates with deficits in interleukin (IL)-1 and IL-6 production in
response to tumor necrosis factor-a (TN Fa) stimulation. In addition there is a
defect in TNFa mediated expression of TNFa and macrophage inflammatory
proteins (MIP) 1 a, MIP1 Band MIP2. p38 MAPK-specific signaling defects were
also observed in lipopolysaccharide (LPS) stimulated mkk3 /-) macrophages.
Additionally, mkk3 /-) macrophages exhibit defects in LPS and CD40- ligand
(CD40L) stimulated IL-12 biosynthesis. Similar data were obtained from CD40L-
stimulated mkk3 /-) dendritic cells. I also observe that interferon (Ifn)-
production is diminished during T-helper- 1 (T H1) differentiation of CD4+ T-cells
derived from mkk3 /-) mice. Taken together these data demonstrate a crucial
role for p38 MAPK activation by MKK3 in response to the inflammatory cytokine,
TNFa and during a T H 1 inflammatory response.
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SPECIFIC AIMS
1). To understand how the mkk3 gene encodes two isoforms, MKK3a and
MKK3b. In addtion, to understand how expression of the murine MKK3b is
regulated.
2). To understand the contribution of MKK3 in regulating signaling to the p38
mitogen-activated protein (MAP) kinase pathway in response to stress and the
inflammatory cytokines tumor necrosis factor (TNF)-a interleukin (IL)-
3). To understand the contribution of the MKK3/p38 MAP kinase pathway during
the development of CD4+ T-cell-dependent inflammatory response.
CHAPTER I
Introduction
Cells in multicellular organism must communicate with each other in order
to regulate growth , development , and to coordinate their functions. This is
accomplished by means of signaling molecules that interact with receptors
located on the surface of cells. A receptor is a protein or complex of proteins
which recognizes a molecule in the cell' s immediate environment. It must be
capable of transmittng information about the molecule to the interior of the
cell- is the molecule harmful , helpful or unimportant? In turn the cell must
interpret this information in such a way that it can mount an appropriate
response. Cells also respond to a wide variety of other chemical and physical
stimuli in their environment including UV irradiation , osmotic shock , heat shock
and DNA damage.
Most cells in a complex organism are specialized to perform a small set of
primary functions. A specific signaling molecule (or stimulus) may have different
effects on different target cells. This is due in part to different receptors for the
same molecule and in part to differences in internal signaling machinery between
different cell types. The mechanism by which a cell converts a stimulus in its
environment into a biological response is known as signal transduction. Signal
transduction is a universal process by which cells respond to stimuli in their
environment and underlies the growth and development of all organisms.
Understanding how signal transduction pathways program cells to perform
specific functions is crucial to our understanding of how cells communicate with
each other in the context of a tissue, organ or an entire organism. Additionally,
dissecting specific pathways is essential for understanding and treating human
diseases including cancer, autoimmune and many other diseases that result from
perturbation of signal transduction pathways.
Identification of 38 MAP kinases. p38 MAP kinase, also known as CSBP and
reactivating kinase (RK), was first identified by several independent groups using
different strategies: it was shown to be a major tyrosine-phosphorylated 38 kD
protein induced by lipopolysaccharide (LPS) in murine macrophage cell lines
(59); to be the target for a group of anti- inflammatory drugs which inhibit IL- 1 and
TNFa synthesis in human monocytes (CSBP , (l00)) and an IL- induced protein
kinase that activates the protein kinase MAPKAPK kinase 2 (RK , (44 , 170)). The
p38 MAP kinase is similar to the yeast HOG 1 MAP kinase which is involved in
osmolarity regulation (Fig1. 1 a) (67). Two p38 MAP kinase isoforms were
identified in Drosophila that appear to regulate immunity gene expression (63).
There are four mammalian isoforms of p38 MAP kinase: p38a; p38B; p38y, and
p388 (Fig 1. 1b) (27 59, 100 103 122 170, 187 214). The
biochemical mechanisms that account for the effects of the p38 MAP kinase
signaling pathway remain unclear. However , recent studies have led to the
identification of substrates for the p38 MAP kinase that may be physiologically
relevant. These include the transcription factors ATF2 (161 , 162), CHOP (215),
ELK- 1 (158, 228), MEF2C (58), and SAP- 1 (158 , 228) which are phosphorylated
and activated by p38 MAP kinase. In addition, the p38 MAP kinase also has
been reported to regulate NF-kB transcriptional activity by a mechanism that has
not yet been defined (212, 253). The p38 MAP kinase has also been reported to
phosphorylate and activate other protein kinases , including MNK1 , MNK2
MAPKAPK2, MAPKAPK3, MSK1, and PRAK (44 109, 118 144 170, 218). It is
likely that these protein kinases may function as effectors for some actions of the
p38 MAP kinase pathway. For example, MAPKAPK2 and MSK1 may mediate
the effects of p38 MAP kinase signaling on the phosporylation and activation of
the transcription factors ATF1 and CREB (78, 144 , 201); MAPKAPK2 may
mediate the effects of p38 MAP kinase signaling on the phosphorylation of
tyrosine hydroxylase and the small heat shock protein hsp27 (44, 170 205), and
the MNK1 and MNK2 protein kinases may contribute to the effects of the p38
'r-
signaling pathway on translation through phosphorylation of eIF-4E (218). There
are many MAPKKK's that can activate MKK3 and MKK6 in vitro but the
physiologically relevant activators that mediate the effects of specific stimuli
remain to be determined (40).
The specific upstream MAPK kinases for p38 MAP kinase are MKK3 and
MKK6 (25, 31 , 60, 61 , 133, 162, 186), although MKK4 , an upstream kinase for
JNKs, has also been implicated in the activation of the p38 MAP kinase pathway
(Fig 1. 1 a) (31 , 46, 104). Both MKK3 and MKK6 are activated upon
phosphorylation on Ser and Thr residues within subdomain VIII by upstream
MAPKK kinases (MAPKKKs). Recent investigations suggest that MKK3 and
MKK6 may differentially regulate p38 MAP kinase isoforms(38). However there
is an isoform of MKK3 (MKK3b) that exhibits similar specificity towards p38 MAP
kinase isoforms as MKK6 (37, , 133). The primary aim of this Dissertation is to
examine the role of MKK3 in mediating signaling to the p38 MAP kinase
pathway.
Signaling from Growth Factor and Cytokine Receptors
nalin from rowth factor rece tors. Binding of ligand to some receptors
activates intrinsic protein kinase activity. These receptors are grouped into two
categories- receptor-tyrosine and receptor-serine/threonine kinases. The
remainder of this discussion will focus on receptor tyrosine kinases (RTK' s).
Several growth factors , such asuepidermal growth factor (EGF) and platelet-
derived growth factor (PDGF), activate intracellular signaling pathways by
binding to and activating RTK's. Generally, ligand binding triggers structural
changes of RTK's including dimerization and stimulation of kinase activity (175).
Activated RTK dimers then auto-phoshorylate (and likely trans-phosphorylate)
residues in their cytoplasmic domains (80, 102, 174). Tyrosine auto-
phosphorylation creates docking sites for cellular proteins including adaptor
proteins and other enzymes. These docking sites are crucial for the recruitment
and activation of a variety of signaling molecules (173). Other docking sites are
required for initiating the formation of signaling complexes that communicate with
MAP kinase modules through cascades of protein phosphorylation.
One class of signaling molecules recruited to activated RTK's are the Src
homology-2 (SH2) and SH3 domain containing proteins. These include a large
.. ."'_. _--, 
number of proteins with different enzymatic activities. Some of these proteins are
responsible for generating lipid second messengers including PLC-y. Another
class of signaling molecules that are recruited to RTK's is the adaptor proteins
(Grb2, Shc, Crk etc. ) that contain only SH2 and/or SH3 domains (reviewed in
(173)). These proteins link receptor activation to downstream signaling events.
For example, Grb2 recruits the Ras guanine releasing factor son-of-sevenless
(SOS) to Ras stimulating GTP for GDP exchange and thus Ras activation (154
176). Once activated, Ras interacts with effector proteins including PI-3 kinase
and the MAP kinase kinase kinase Raf (124, 173 217).
nalin from C tokine Rece tors. Tumor necrosis factor-a TN Fa),
interleukin- 1 (IL-1) and lipopolysaccharide (LPS) have a broad range of
physiological effects. These include lymphocyte and leukocyte activation and
trafficking, fever, acute-phase response and cartilage remodeling (7). TNF and
IL- 1 trigger the activation of transcription factors NF-KB and AP- 1 (among others)
which regulate expression of genes involved in the inflammatory response (179).
Unlike growth factors , receptors for the inflammatory cytokines IL-1 and TNFa
lack intrinsic enzymatic activity. Ligand binding triggers oligomerization resulting
in the recruitment of signaling molecules largely through homotypic interactions.
.,...
TNFa si nalin . The type 1 TNF receptor (TNFR1) represents a superfamily of
cell surface receptors including FAS, CD27, CD30, CD40 and many others (73
74). This class of receptors mediates cellular responses through the recruitment
of adaptor proteins (Fig 1.2). The TNFR1 contains a structure known as a death
domain in the cytoplasmic tail (203). As it's name suggests, the TNFR1 death
domain mediates the death (apoptosis) signal in response to TNF-a (203). The
death domain of TNFR1 interacts directly with TNFR1-associated death domain
protein (TRADD) (73, 74). TRADD functions as a molecular scaffold recruiting
additional proteins including Fas-associated death domain protein (FADD),
TNFR1-associated factor-2 (TRAF2), and receptor interacting protein kinase
(RIP) (72, 88 , 250). FADD communicates a signal from TRADD to the caspase
pathway stimulating apoptosis (19, 247). Another bifurcation of the TNFR1
signaling pathway just downstream of TRAF2 results in activation of NFKB and
AP1 dependant gene transcription (17). TRAF2 is likely to be responsible for
recruiting RIP and NFKB- inducing kinase (NIK) to the TNFR1 signaling complex
(197). Both RIP and NIK are implicated in initiating kinase cascades leading to
nuclear translocation of NFKB and activating the SAPK p38 and JNK. However
RIP deficient cells are selectively defective in mediating TNF induced NFKB
activation (88). In addition , dominant negative NIK selectively blocks activation of
NFKB by TNF without affecting p38 or JNK activity (185). However, nik /-) cells
;r.
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signal normally to NFKB in response to TNF-a. These observations are
consistent with a report that suggests that NIK may be redundant with MEKK1 in
the NFKB pathway (7). In contrast, TRAF2 appears to playa minor role in
cytokine induced NFKB activation (145 , 248). The primary role for TRAF2 may be
to activate JNK and p38 signaling modules in the TNFR1 signaling pathway.
IL-1 and LPS si nalin . Binding of IL-1 to its receptor initiates the formation of
a signaling complex that is substantially different from that formed by TNF. IL-
binding induces IL- 1 R1 heterodimerization with IL- 1 R1 accessory protein (IL-
R1AcP). This heterodimer binds the adaptor protein Myd88 mediating the
association of the complex to IL-1 receptor-associated kinase (IRAK) and
TRAF6. TRAF6 then mediates many of the downstream events including NFKB,
JNK and p38 MAP kinase activation. Many of the same proteins implicated in IL-
1 signaling are involved in LPS signaling and are discussed below.
LPS signaling through the LPS receptor CD14 utilizes the human toll- like
receptors , TLR2 and TLR4 (Fig 1.2). Expression of human TLR2 renders cells
responsive to LPS (89). Recent reports suggest that TLR4 may be LPS-specific
whereas TLR2 may be the receptor for gram-positive bacterial cell wall
components (198). Binding of LPS to CD14 triggers TLR oligomerization and
activates NFKB together with the JNK and p38 MAP kinase signaling pathways
(141, 198). Oligomerized TLR recruits adaptor proteins by homotypic interactions
utilizing the Toll/IL-R1 (TIR) homology domain (Fig 1.2) (120). TLR utilize the TIR
protein Myd88 to recruit the pelle-related protein kinase IRAK to the receptor
(142 224). The function of Myd88 is ilustrated by the observation that mice with
a targeted disruption of the myd88 gene are unresponsive to IL- 1 and LPS (2
86). Finally, TRAF6 is recruited , likely through a direct interaction with IRAK (16).
Many of the same proteins involved in IL- 1 R signaling are recruited to activated
CD14/ hTLR upon LPS binding suggesting that downstream signaling events are
likely to be similar between the two pathways (Fig 1.2). In addition , IL-1 and
TLR2 signaling share common features with TNF receptor signaling although
there are some fundamental differences.
One primary difference between the TNF and IL- 1/TLR pathways is the
molecular ordering at the level of TRAF2 and TRAF6 respectively. In the IL-
1/TLR pathway, TRAF6 appears to be primarily responsible for activating the
transcription factor, NFKB. The signal may be relayed from TRAF6 to NFKB by a
succession of protein kinases including TGFB-associated kinase-1 (TAK1), NIK
and IKB-kinase (IKK) (105, 148). IKK phosphorylates IKB targeting it to the
proteasome for degradation (121 , 192, 252). This frees NFKB for nuclear
translocation and transcriptional activation. I RAK is also responsible for
transmitting the IL-1 signal to the p38 and JNK cascades and appears to involve
TAK1(148). Thus, like the TNF pathway, signaling from the IL-1 receptor and
TLR' s bifurcates at the level of a TRAF protein. However, the functions of IRAK
and TRAF6 in transmitting the signal from the receptor to JNK and p38 MAP
kinase modules are different from those of RIP and TRAF2. Events downstream
of IRAK in the IL- 1/TLR pathways leading to JNK and p38 MAP kinase activation
remain unclear. For example, dominant negative TRAF6 fails to block hTolI-
induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases
(141). In addition, traf6 /-) cells fail to activate JNK or NFKB in response to LPS
(107). Also, TRAF6 may directly target IKB for proteolysis by a MAP kinase
kinase kinase- independent IKK/ubiquitin dependent mechanism (30). Finally, 
recent report identified ECSIT (
.volutionarily .Qonserved ignaling intermediate in
oll pathways) as a novel component of the IL-1/Toll signaling pathway that links
TRAF6 to MEKK1 and activation of the JNK and NFKB pathways (91). TRAF2 is
required for activation of the JNK signaling pathway in response to TNF-a (248).
TRAF2 was reported to interact with the MAPKK MEKK1 and ASK1 , two
MAPKKK that activate the JNK signaling pathway (7 , 150 237). The mechanism
by which TRAF2 interactions with MEKK1 and ASK1 activate the JNK signaling
pathway is unclear. Similarly, it is not known if there are functions for other
. .
MAPKKK in this signaling pathway (28). One possible mechanism linking
cytokine induced GCK and MAPKKK activation to JNK and p38 MAP kinase
signaling is through the formation of specific signaling complexes.
Signal Transduction by MAP kinase pathways
Mitogen-activated protein kinase signal transduction pathways have been
implicated in multiple physiological and pathophysiological processes , including
growth , differentiation, cell survival and cell death (79, 123 , 227). In the yeast
Saccharomyces cerevisiae MAP kinase signaling pathways are required for
mating of haploid cells. Binding of mating pheromone to a G protein-coupled
receptor stimulates a MAP kinase module comprised of Ste11 , Ste7 and Fus3
(Fig. 1. 1) (reviewed in (229)). Fus3 activates transcription of mating genes
promoting differentiation of haploid S. cerevisiae into mating-competent cells. In
mammals , three groups of MAP kinases have been identified: the extracellular
signal-regulated protein kinases (ERK), the c-Jun NH terminal kinases (JNK),
and the p38 MAP kinases. These MAP kinases are activated by conserved
protein kinase signaling modules which include a MAP kinase kinase kinase
(MKKK), and a dual-specificity MAP kinase kinase (MKK). The M KKK
phosphorylates and activates the MKK , which in turn , activates the MAP kinase
by dual phosphorylation on threonine and tyrosine residues within a Thr-Xaa-Tyr
motif located in protein kinase subdomain VIII (Fig 1. 1 b) (123 , 227). Separate
protein kinase signaling modules are employed to activate different groups of
MAP kinases (Fig. 1. 1 a) (31). These signaling modules are coupled to different
environmental stimuli. For example, the ERK MAP kinases are activated by a
Ras-dependant pathway in response to many growth factors and hormones
(227). In contrast, the JNK and p38 MAP kinases are activated by environmental
stresses, such as UV radiation , osmotic shock, heat shock, and chemical factors
including protein synthesis inhibitors and lipopolysaccharide (79 , 123). The JNK
and p38 MAP kinases also are activated by treatment of cells with
proinflammatory cytokines, including interleukin-1 (IL-1) and tumor necrosis
factor (TNF) (79, 123).
The JNK and p38 MAP kinase pathways are referred to as stress-
activated MAP kinase (SAPK) pathways since they are both activated by
environmental perturbation (e.g. osmotic changes, heat shock) and by
inflammatory cytokines including tumor necrosis factor a (TNF-a) and interleukin-
1 (IL-1). The physiological functions of the JNK and p38 MAP kinase pathways
might therefore be overlapping (79). Biochemical and genetic studies have
revealed the roles of the JNK pathway as regulators of apoptosis (32 , 239, 243),
development (182, 241), cell transformation , T-cell activation and differentiation
(34, 188, 242) and cytokine production (194). Similarly, the p38 MAP kinase
pathway has been proposed to function in the regulation of cytokine production
(9, 100, 167), B cell and T cell proliferation and differentiation (23 , 167 , 189), the
innate immune response (63 , 79), cell cycle control (130, 196), and apoptosis (75
83, 216, 239).
The immediate upstream activators of the JNK group of MAP kinases are
MKK4 and MKK7. Recent evidence suggests that signaling from cytokine
receptors to JNK may selectively utilize MKK7 (41 , 134). In addition MKK7 is
activated by the GTPase Rac (69). MKK7 but not MKK4 selectively interacts
with the JIP group of molecular scaffold proteins (87, 226, 246). JIP also directly
interacts with JNK , MLK3 and the Ste20 related protein kinase, HPK1 (87, 226
246). These observations suggest that the formation of specific complexes may
define selectivity of JNK activation by MKK4 and MKK7 in response to various
stimuli. Similar selectivity in the p38 MAP kinase signaling pathway regarding
activation by MKK3 versus MKK6 has not been identified. However, two recent
reports demonstrate that MKK6 and MKK3b (but not MKK3a) contain an amino-
terminal domain which may mediate selectivity in the p38 MAP kinase signaling
pathway (37 , 38).
nalin in the immune s stem. The adaptive branch of the immune system
is an important area to study signaling by the stress-activated protein kinases.
Both Band T-cells undergo complicated patterns of development from naive
precursor cells to highly specialized effector cells. Upon antigen stimulation
CD4+ T-cells differentiate into two distinct subsets (137, 138). These two
subsets, T H 1 and T H2 cells, are responsible for cell-mediated inflammatory and
humoral immune responses, respectively. (136, 138, 151 , 153). The signature
cytokines of TH1 cells are IFN-y, IL-2 and TNF-B which are involved in cell
mediated inflammatory reactions (153). T H2 cells secrete mainly IL- , IL-5, IL-
IL- 10 and IL-13 mediating B-cell activation and antibody production (153). The
selective differentiation of naive T-cells into T H 1 or T H2 cells depends largely on
antigen dose , the source of co-stimulation and the cytokine environment (22).
The most potent polarizing factor is the cytokine environment during stimulation.
IL-4 drives the differentiation of TH cells whereas IL-12 promotes TH
development (98 , 193). Recent reports have demonstrated that the JNK and p38
MAP kinase pathways are involved in the developmental decision between a T 
H 1
and a T H2 response (167 , 188 , 242). Targeted disruption of the jnk1 or the jnk2
genes resulted in attenuated T H 1 responses (34, 242). This was a result of the
inability to down-regulate production of T H 2 cytokines Unk1 /-)) or decreased IL-
12-stimulated IFN-y production Unk2 /-)) (34, 242). The p38 MAP kinase
signaling pathway has also been implicated in the T H 1 response. Transgenic
mice expressing a dominant negative p38 MAP kinase exhibit a selective defect
in the T H1 response (167). Pyridinyl imidazoles (inhibitors of p38 MAP kinase)
block IFN-y production by T H1 cells without affecting IL-4 production by T H2 cells
(167). In contrast , transgenic mice expressing constitutively active MKK6
exhibited increased production of IFN-y during differentiation and activation of
T H 1 cells (167). Thus the immune system provides useful models for examining
the contribution of different MAP kinase signaling pathways to the execution of
an inflammatory response.
Figure 1.1 MAP kinase modules: The Erk, JNK and p38 pathways.
Five MAP kinase signaling pathways have been identified mammals, three of
which have been extensively characterized: the Erk , JNK and p38 MAP kinase
pathways. (A) The three-tiered MAP kinase module is conserved from the yeast
Saccharomyces cerevisiae to humans. Illustrated are the three kinase modules
comprising the MAP kinase signaling pathways. 
(B) The p38 group of MAP
kinases is comprised of four members: p38a; p38B; p38y, and p388. Illustrated is
the conservation between p38 MAP kinase isoforms in the activation domain.
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Figure 1.2 Cytokine signaling pathways.
Inflammatory cytokines and LPS activate the JNK and p38 MAP kinase signaling
pathways. Illustrated is a diagram of signaling events occurring upstream of the
conserved JNK and p38 MAP kinase modules in response to TNF-a and LPS
(adapted from Tony Pawson and Piers Nash, Genes and Dev. 2000 14: 1027-
047)
TN
Fa
CD
14
R
IP
N
F-
pa
th
w
ay
IR
A
K
IR
A
K
'S
.I
TR
A
F2
EC
SI
T
TR
A
F6
a
ct
iv
e 
ca
sp
as
e 
8
JN
K 
an
d 
p3
8
pa
th
w
ay
s
M
EK
K
1
.
I \
N
F-
pa
th
w
ay
JN
K 
an
d 
p3
8
pa
th
w
ay
s
ap
op
to
sis
Ad
ap
te
d 
fro
m
 T
on
y 
Pa
ws
on
 a
nd
 P
ie
rs
 N
as
h
G
e
n
e
s
 
a
n
d 
De
v.
 
20
00
14
: 
10
27
-
10
47
CHAPTER II
STRUCTURE AND REGULATION OF THE MURINE Mkk3 GENE
Abstract
Molecular cloning studies identified two human isoforms of MKK3,
(MKK3a and MKK3b) which exhibited different substrate specificity (31 , 61 , 133).
Sequence comparison of the MKK3 cDNA identified a 29 amino acid NH2
terminal extension in MKK3b relative to MKK3a (Fig 2. 1 a) (37, 61 , 133). Cloning
and characterization of the 23. kilobase (kb) murine mkk3 gene illustrated that it
consists of 12 exons interrupted by 11 introns. Comparison of the human and
murine mkk3 genes demonstrated that they diverge in the 5 -region. The murine
mkk3 gene encodes a single MKK3 isoform , MKK3b , whereas the human gene
encodes both MKK3a and MKK3b. The DNA sequence upstream of the
translation initiation codon in the murine mkk3 gene encodes multiple cis-acting
elements predicted to interact with many transcription factors. These include
potential binding sites for the transcription factors MyoD, MEF2, AP1/PEA1 , AP2
NF-KB , and PEA3/Ets. The structure and sequence of the human and murine
mkk3 genes suggest mechanisms for generation of alternate isoforms of MKK3
in humans and for maintenance of robust MKK3b expression in skeletal muscle.
Introduction
The p38 MAP kinase kinases MKK3 and MKK6 selectively activate the p38 group
of MAP kinases. p38a is also activated by MKK4 in vitro but the significance of
this observation is unclear (31). MKK6 is a common activator of p38a, p38B2;
p38yand p388 MAP kinase , while MKK3a activated only p38a, p38yand p388
MAP kinase (27 214). However, recent reports identified cDNA
encoding two isoforms of MKK3 (MKK3a, and MKK3b) that have different
substrate specificities (61 , 133). MKK3b , unlike MKK3a, activates p38B2 together
with p38a, p38y and p388 MAP kinase (37, 38). The amino acid sequences of
MKK3a and MKK3b are identical with one exception. MKK3b has a 29 amino
acid NH2 terminal extension relative to MKK3a (Fig. 2. 1 a) (37, , 133). The NH2-
terminal extension of MKK3b encodes a docking domain , conserved in MKK6 but
absent in MKK3a, that mediates MKK interactions with p38a and p38B2 MAP
kinase (37). These observations demonstrate that MKK3 isoforms differentially
activate the p38 MAP kinase signaling pathway. Expression of two MKK3
isoforms with different substrate specificity suggests that they may differ in their
physiological function. These MKK may be coupled to different upstream
signaling pathways. Alternatively, these MKK3 isoforms may differ in their tissue
distribution. Northern blot analysis has demonstrated that MKK3 mRNA is
Figure 1. Comparison of MKK3a and MKK3b.
(A) Amino Acid sequence of human and murine were compared and aligned
using the GCG (University of Wisconsin Genetics Computer Group) programs
Pileup and Pretty. The initiating methionine in human MKK3a is indicated by a
star. Amino acids comprising the p38 MAP kinase-docking site are indicated by
the symbol delta. (B) Nucleotide sequence of human mkk3 cDNA and murine
mkk3 gene (exon 2) were compared and aligned as described above. The
initiation codon (ATG) in human MKK3a is indicated by a star.
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ubiquitously expressed and is enriched in skeletal muscle (31). Thus, MKK3
expression may be positively regulated in skeletal muscle although the
significance of this observation remains to be tested.
MyoD is a member of the bHLH group transcription factors that includes
myogenin , Myf5 (15) and Myf6 (14 , 125 , 165). These transcription factors are also
known as muscle regulatory factors (MRFs). MRFs promote skeletal muscle
differentiation by binding to a consensus sequence termed an E-box , present in
the promoters of many muscle specific genes (6, 8, 114, 128, 180, 225, 251).
Induction of MRF activities may be the result of extracellular signals such as
insulin or insulin like growth factors known to promote terminal differentiation of
myoblasts by activating multiple MAP kinase pathways including the p38
pathway (131). The p38 MAP kinase enhances the ability of MyoD to convert
fibroblasts to muscle (235 , 254). Treatment with the p38 inhibitor, SB203580,
blocks the myogenic conversion of L8 and C2C12 cells to multinucleated
myotubes and also inhibits MyoD activity in transfected fibroblasts (26 , 99 , 235
254).
Several lines of evidence suggest that MRF require a co-factor for muscle
specific gene expression. One class of candidates for MRF co-regulator
activities is the myocyte enhancer factor-2 (MEF2) family of transcription factors.
MEF2 proteins are encoded by four genes in mice and humans and are referred
to as mef2A , mef28, mef2C and mef2D (36 116 135 191). MEF2 proteins
alone cannot induce myogenesis in transfected fibroblasts. However when co-
expressed with MyoD or myogenin they enhance the extent of myogenic
conversion above that seen with either MRF alone (127 , 129, 143).
MEF2A and MEF2C are both phosphorylated by p38 MAP kinase within
the MEF2 transactivation domain. These phosphorylations regulate MEF2
transcriptional activity and thus playa positive role in regulating MEF2-dependent
gene expression. The p38 MAP kinase may enhance MyoD induced myogenic
conversion by activation of MEF2A or MEF2C (245 , 256). MyoD may also be
regulated directly by the p38 MAP kinase signaling pathway (160). The
mechanism by which p38 MAP kinase activity is modulated during muscle
differentiation remains unclear. One possibility is that regulation of p38 MAP
kinase activity occurs at the level of expression of its upstream activators. For
example , the JNK MAP kinase activators MKK4 and MKK7 are differentially
expressed during T-cell development (223).
The purpose of this study was to examine the structure and regulation of
the murine mkk3 gene. These data show that two factors contribute to the
regulation of mkk3 expression: (i) differential promoter utiization resulting in the
expression of the MKK3a and MKK3b isoforms in humans; and (ii) sequences in
mkk3 flanking region that support a mechanism for maintaining robust
expression of murine MKK3 in skeletal muscle. Together these data provide
insight into the mechanisms regulating mkk3 expression.
Materials and Methods
Materials. 10T1/2 fibroblasts were from American Type Culture Collection32 32 35 
(ATCC). (a- P)ATP (a- P)UTP and (a S)ATP were obtained from DuPont-
NEN. Restriction enzymes, T4 DNA ligase, T4 polynucleotide kinase , and
Klenow enzyme were obtained from Boehringer-Mannheim. The expression
vector pCDNA3-MKK6(glu) has been described elswhere (162). The expression
vectors pCS2, pCSA-E12, pCSA-MyoD, and pCDNA3-MEF2C (117) were
provided by A. Lassar. The expression vectors pCDNA 1 Amp-MEF2A
pCDNA1Amp-MEF2B , pCEFL-MEF2C, and pCEFL-MEF2D (256) were provided
by E. Olsen. The expression vectors pCDNA3-MEK5(glu) and pCDNA-ERK5
(115 , 240, 258) were provided A. Sharrocks.
Clonin and Characterization of the murine mkk3 ene. Genomic clones
corresponding to the mkk3 locus were isolated by screening a AFix II murine
genomic library (Stratagene) using a human MKK3a cDNA as a probe. Three
overlapping clones encompassing the sequence of the entire murine MKK3b
cDNA were characterized by a combination of restriction digestion , Southern
blotting and DNA sequencing analysis using an Applied Biosystems model 373A
instrument.
Characterization of the human mkk3 ene. The human mkk3 gene sequence
was assembled from overlapping contigs deposited into Genbank from the
human genome sequencing project (Eric Lander , MIT).
FISH fluorescence in situ bridization . Lymphocytes isolated from male
mouse spleen were used for chromosomal FISH analysis (65 , 66). Metaphase
chromosomes spread on a glass slide were air dried , baked at 55 C (1 h), and
digested with RNase A. The DNA was denatured for 3 min at 70 C in 70%
formam ide in 2X SSC (1 X SSC is 0. 15 M sodium citrate) and dehydrated with
ethanol. DNA prepared from mouse mkk3 genomic clones was biotinylated and
use as a hybridization probe (65). The FISH and 4' diamidino- phenylindole
(DAPI) staining were recorded on film. The assignment of the FISH mapping
data with chromosomal bands was achieved by superimposing the FISH signals
with images of the DAPI-banded chromosomes.
Plasmid construction. The murine mkk3 promoter-Iuciferase fusion vector
pGLUC-MKK3.5 was made by ligating a 3,404 bp Xba I to Rsr II restriction
fragment of the 5' flanking region into pGL3- Basic (promega) digested with Xba 
and Nco The mkk3 promoter deletion series pGLUC-MKK3.6, pGLUC-
MKK3. , pGLUC-MKK3. 8, pGLUC-MKK3.9, pGLUC-MKK3. 10 and pGLUC-
MKK3. 11 were constructed by removing progressively larger fragments of the
mkk3 region from the reporter plasmid pGLUC-MKK3.5 using standard
techniques.
Cell culture. 10T1/2 fibroblasts were cultured in minimal Eagle s medium (MEM)
supplemented with 10% heat inactivated fetal bovine serum, 2 mM glutamine,
100 U/ml penicillin , and 100 U/ml streptomycin in a humidified environment with
5% CO Transient transfections were performed with the LipofectAMINE
reagent (Life Technologies) according to the manufacturer s recommendations.
Mkk3 orter ene ex ression. Plasmids encoding a luciferase gene driven
by the murine mkk3 promoter were co-transfected into 10T1/2 fibroblasts
together with expression constructs encoding MyoD , E12, MEF2A, MEF2B,
MEF2C, MEF2D without or with constitutively active forms of MKK5, MKK6
(MKK5(glu), and MKK6(glu)) or ERK5. Cells were grown in 6-well multi-well
plates (Costar) and transiently transfected with 2 J.g of total plasmid DNA per
well. A B-galactosidase expression plasmid (pCH11 0, Pharmacia LKB) was used
to control for transfection efficiency. The total amount of DNA was kept constant
by using the empty vector pCS2 (A. Lassar). After 36 hours the medium was
changed to differentiation medium (MEM/ 2% heat inactivated horse serum/ 2
mM glutamine/ 100 U penicillin per ml/100 units streptomycin per ml/ 10 1l9/ml
insulin/5 Ilg/ml transferrin/ 10 nMol sodium selenate). 60 hours after transfection
cell extracts were prepared and the activities of B-galactosidase and luciferase
were measured as described below.
Luciferase and lactosidase assa s. Cells were scraped from each well of a
six-well tissue culture plate in 300 III of 0. 1 M potassium phosphate (pH 7.4)/ 
mM PM SF. Cells were lysed by four freeze thaw cycles (freeze on crushed dry
ice, thaw at 37 C). Cell debris was pelleted by centrifugation at 14 000 rpm in a
microcentrifuge at 4 C for 15 minutes. Luciferase reactions were performed by
adding 10 III clarified cell lysate to 350 III of assay buffer (25 mM glycylglycine pH
15 mM KP04 pH 7. 15 mM MgS04' 4 mM EGTA, 2 mM ATP , 1 mM DTT)
and 100 ul D- Iuciferin (1 mM D-Iuciferin, 25 mM mM glycylglycine pH 7.8, 1 mM
DTT). Luciferase activity was measured using the Monolight 2010 luminometer
(Pharmingen). B-galactosidase activity was measured on a SpectraMAX 250
plate reader (Molecular Devices).
RNA isolation and rimer extension anal sis. Total RNA was purified from
5 g (wet weight) of mouse liver using RNA-Stat reagent (TeITest) according to
the manufacturer s recommendations. The 18 residue oligonucleotide MKK3.
TCATGGCTGCTGGTGTCT- ) complementary to nucleotides +259/ +242 in
the murine mkk3 5' flanking region was end- labeled using T4 polynucleotide
kinase (promega) and (a- P)ATP. The labeled primer was annealed to yeast
tRNA (20 J.g) (control) or adult mouse liver total RNA (20 J.g) and extended with
AMV reverse transcriptase (Promega) according to manufacturer
recommendations. Chain termination sequencing reactions were performed with
the above primer and a segment of the mouse genomic DNA containing the
mkk3 5' flanking sequences using a T7 Sequenase Quick-Denature Plasmid
Sequencing kit (Amersham Corp. ) and (a S)ATP. Reverse transcripts were
analyzed on a 6% acrylamide , 8M urea gel in parallel with chain termination
sequencing reactions.
Results
Structure of the murine mkk3 ene. MKK3 has been identified as a specific
activator of the p38 group of MAP kinases. Several overlapping genomic clones
encoding MKK3 were isolated. Sequencing of the murine 
mkk3 gene (23.6 kb)
revealed the presence of 12 exons interrupted by 11 introns (Fig. 2. , 2.3a).
Initiation codons in-frame with upstream termination codons are located in exon
one of the murine mkk3 gene. Exon one also encodes the first 16 residues of
the amino terminal extension found in MKK3b together with the 5' -untranslated
region (UTR) and includes potential transcriptional regulatory elements (see
below). Exon two of the murine mkk3 gene encodes the amino terminus of
MKK3a but does not encode the initiation codon (ATG) found in human MKK3a.
Instead the murine mkk3 gene contains a valine codon (GTG) at this position.
Sequences upstream of the valine codon in exon 2 share significant homology
with the 5' -sequences of human MKK3 cDNAs and encode 13 amino acids of the
NH2 terminus found in murine MKK3b.
Murine genomic clones encoding MKK3 and a MKK3 pseudo-gene were
isolated. FISH analysis led to mapping of mkk3 to mouse chromosome 11 region
B1. 3 whereas the mkk3 pseudogene maps to chromosome 4 region C6 (Fig.
2b). Data from the Genome Project maps human mkk3 to chromosome
17q11.2. The human mkk3 gene consists of 15 exons interrupted by 14 introns
(Fig 2.2a). Comparison of the human and murine mkk3 genes reveals
differences in the structure of the 5 terminus. Like the murine gene, exon one of
the human mkk3 gene encodes the first 16 residues of the amino terminal
extension found in MKK3b. However, the human mkk3 gene contains three
additional exons encoding the 5' UTR of MKK3a (Fig 2.3a). Exon 5 of the human
gene shares homology with exon 2 of the mouse gene and encodes the
translation initiation codon found in the human MKK3a cDNA. These
observations suggest that the human MKK3a and MKK3b messages are
transcribed from different promoters.
Determination of transcri tion start sites for murine mkk3. Exon 1 of the
murine mkk3 gene encodes the translation initiation codon and the first sixteen
amino acids of MKK3b. Identity between the cDNA and genomic sequences
extends 153 nucleotides upstream of the initiation codon (ATG). To determine
the 5' terminal region of MKK3b mRNA primer extension analysis was performed
on yeast tRNA (control) or mouse liver total RNA using anti-sense
oligonucleotides complementary to the 5 UTR of MKK3b. Primer extension with
the oligonucleotide MKK3.91 (5 TCATGGCTGCTGGTGTCT- ) resulted in one
Figure 2.2. Identification and chromosomal localization of the murine mkk3
gene
(A) The murine mkk3 gene was characterized by a combination of Southern blot
analysis and DNA sequencing using an Applied Biosystems model 373A
instrument. There are 12 exons interrupted by 11 introns. The human mkk3
gene was compiled from sequences deposited in Genbank (Eric Lander, MIT).
The human mkk3 gene has 15 exons interrupted by 14 introns. Exons are
represented by black boxes and designated with numbers. Introns are
represented by a line between exons are designated in letter code. Grey boxes
adjacent to exons 1 and 12 (mouse) and 15 (human) represent 5' UTR and 3'
UTR respectively. Hatched boxes indicate exons removed by splicing of mkk3
mRNA (B) Fish analysis of murine mkk3 was performed on murine lymphocyte
metaphase chromosomes using DNA prepared from mkk3 and mkk3-
pseudogene genomic clones as probes. White numbers indicate the
chromosomal localization.
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major and three minor reverse transcripts (Fig. 2.4). The major transcript started
324 nucleotides upstream of the translation initiation codon. The nucleotide
corresponding to the 5 terminus of the major transcript was designated as + 
and will be used as a reference to describe the relative positions of promoter
elements and restriction enzyme sites used to make various reporter constructs.
ulator elements in the 5' flankin uence of the murine mkk3 ene.
To identify cis-acting elements that may regulate murine MKK3b transcription
3,404 bp of of the 5' flanking sequence was determined (Fig. 2. 5). The 300 bp of
sequence surrounding the transcription start sites has high GC-content (68%).
There was no canonical TATA or CCAAT box near the start site. However there
were six Sp1 core binding sites distributed around the transcription start sites.
One Sp1 site is located upstream of the major start site (at -18 nucleotides) with
the five other Sp1 sites located downstream (at +62, +77 , +93, +113 and +169
respectively) .
A computer-assisted search of the mkk35 flanking region utilizing the
University of Wisconsin Genetics Computer Group (GCG) program FindPatterns
together with TFSITE database revealed the presence of multiple cis-acting
elements with homology to known binding sequences for a variety of transcription
Figure 2.3. Structure of the murine mkk3 gene.
(A) The murine mkk3 gene was characterized as described above. Illustrated
are 23.6 kb of genomic sequence. Introns are represented by a line between
exons and are designated in letter code. Grey boxes adjacent to exons 1 and 12
represent 5' UTR and 3' UTR respectively. Individual genomic clones are
illustrated by lines below the genomic structure. (B) Represented are the
predicted mRNA splice junctions in the murine mkk3 gene. Also illustrated is the
relationship between the intron-exon and domain structures of the mkk3 gene
and MKK3 protein respectively
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Figure 2.4. Determination of transcription start sites for murine MKK3b.
Primer extension analysis was performed on yeast tRNA (20 Ilg) (control) or
adult mouse liver total RNA (20 Ilg) as described in Materials and Methods. (A)
Reverse transcripts were resolved on a 6% denaturing polyacrylamide gel
together with chain termination sequencing reactions generated by the same
oligonucleotide used for the primer extension reactions. Extension products are
indicated by arrows. The single major transcript is indicated by a heavy arrow.
(B) An aliquot of the samples described above were electrophoresed for an
extended time to better resolve the sequencing ladder in the area of the major
reverse transcript. The major reverse transcript is indicated with an arrow. The
sequence surrounding the start site is shown with the initiating nucleotide
indicated with a star.

!,, ...
factors (Fig. 2.5). These include six MyoD/E-box sites, three MEF2 sites, two
AP1/PEA1 sites, one AP2 site , one NF-KB site , and four PEA3/Ets sites.
Promoter activit of the 5' flankin ion of the murine mkk3 ene. MKK3
mRNA (together with MKK6) is enriched in skeletal muscle (31 , 61 , 133).
Furthermore the MyoD and MEF2 families of muscle specific transcription factors
have been implicated as regulators of skeletal muscle development (10, 36
143, 152 202 219-222 232 233). These observations, together with the presence
of MyoD and MEF2 binding sites in the 5' flanking region of the mkk3 gene
suggested that MKK3b expression may be regulated during skeletal muscle
development or regeneration. Weintraub and others have described an 
in vitro
differentiation protocol during which forced expression of MyoD and E12 in
10T1/2 fibroblasts activated a developmental program reminiscent of skeletal
muscle development (15 , 29). A similar approach was utilized to examine
regulation of murine mkk3 reporter gene expression. A reporter plasmid
containing the -3086 to +317 region of the murine mkk3 gene driving a firefly
luciferase gene was transfected into 1 OT1 /2 fibroblasts and luciferase activity
was examined during in vitro differentiation. Luciferase activity was strongly
induced by co-transfection with MyoD and E12 (Fig. 2.6a). In contrast,
expression of the different MEF2 proteins alone had little or no effect on 
mkk3
promoter activity (Fig. 2.6b). These data demonstrate that mkk3 expression can
be regulated by MyoD and E12. The absence of MEF2 stimulation of mkk3
promoter activity may be due to the presence of endogenous MEF2 proteins in
1 OT1 /2 fibroblasts.
Members of the MEF2 family of transcription factors induce myogenesis in
transfected fibroblasts only when co-expressed with myogenic bHLH proteins
MyoD or myogenin. Furthermore, MEF2A and MEF2C are phosphorylated and
activated by p38 MAP kinase (58, 245 , 256). Therefore the ability of MKK6(glu)
and different MEF2 proteins to activate expression of an MKK3b- luciferase
reporter was tested. A recent report also indicates that MyoD is activated by the
p38 MAP kinase signal transduction pathway (160). MyoD transactivation of the
MKK3b promoter was enhanced by co-expression with MKK6(glu) (Fig. 2.7a). In
addition, transactivation of the MKK3b promoter was greatly diminished by
treatment of cells with the p38 MAP kinase inhibitor SB203580 (Fig. 2.7a). 
contrast, co-expression of MEK5(glu) and Erk5 had no effect on MyoD and MEF2
transactivation of the MKK3b promoter (Fig. 2.7b). Co-expression of MEF2
isoforms with MyoD/E12 and MKK6(glu) had litte additional effect on MKK3b
promoter activity. Thus the p38 MAP kinase signaling pathway may enhance
3007
2937
2867
2797
2727
2657
2587
2517
2447
2377
CAGAAGGCAGGTGAAGGCTCCATGATCTGTCAGACGGGAGTTTGAAGAACAACCCTGTCATTGCAGT
GGTCATGTGTCTCCATCCTCTGCTTGCTTCTCTTTCTTCCTTTCTTTCTTTCTTCCTTCCTTCCTTCTTT
CTTTCTTTTCTTTTTTCTTTCTTTCTTTTTTTCCCTAGACTGGCTTTGAACTCTCGGAGCTTTGCCTGCC
TCTGCCTCCCAAGTGTTGGCATTAAGGTGTGTGCCACAACTGCCTGGCAATCCTTTGCTTTCTGTTCTG
.:: ):-
TTCTGTGCCCATGAATGCACACCTCCTTGGGAGGTGTATGTTCTGAGTGTTCAGTGAGTGCCTACTGT
GCACTGTGGAAGCCAGGAGCCAAGTGTGGTGCTGCTCTCTACAGCTTGCCTCAGAAGGAGTCTGCATGAA
GGACCACCACACAGTAGGTAGGGCTGTGAATGGCATATGCTGTTGTACAGGTAGTGTCATGTCACACG
TATGAATTATCATGTGATATTTCAATGGTGGCCATTTAATACAGAAGGTTAAGAATATACCTAA
GAGGTAAGTATCCCTTGTGTTTCTTCATATGGCAGAGGAAGGACATTCCTGGCTGAGGGGACAGCCTTTG
AAGATCGGATCAAGAAGGAAGCTTGGTTTTGAAGTGTCTGGATATGTCAACAGGGCCAGAGGGTTGG
2307 AATTCCTACCTAGGGAACCAGGAAGATCTGAGCTGGGCCTAGCCCGGCTTTCAGAACTCTCTTTGC
2237 AGCAACTAGCACAGAAGTGAGAAGCTGGGCAGCAGGCAGAGCACAGAGGGTATCGTTTTATCCTGAGTG
2167 GGGCACCCACAGAGAACAGCCACACTAGGGCTGGTCACAAGAAGGCACACACCCCAGGTCAGCAAGCCTT
2097 GGGAGGTTCTGCAGATGGCAGGACACTGCACATACAACCAGAGCTGTGCATGACCACTGTGCCTGTCAAT
2027 AGGCCTGCCCCTGGGCAGCCATGCTAATGCATACAACCCTGTGCATCTTGTGGGAATTCATGTGTGCT
1957 TGGTGTATGATCAGTGCATGCGGAGGAGGCTCTAACAGCATCTGGAAGGGGCTGCATCTGAGGGAGCC
1887 TCTCATTTCTGACCATACCAGTGGTGACACAATTGGTTTGGGGGCTTTCGCTTCTTCTCTTGGAGATTCT
1817 ATCCTTTCTCTTGCTTCTTTAATCTCTGCTTCTGTGGCACCTTTAAGGGAGGCTTTTCCTGACTGCCCT
.:J:: 1C.
1747 CACTAATCACACTCCCACCTCCAGACACACCTTCTCTCGTCCCCTTTTTTCCACAGCATTTGTCACC
1677 TGAGACACCCTATCATTTCACTTAGGCCAGAAGTCCATTCCTTTCTGAGAGCAGCGTTGTGTCTGTTTTG
1607 TTCGTCGTTGATCCCACAATGCTACATCCACAGTGTGTGCTCACCAGTGAGTTGCTCCCCACACACTAG
1537 GTTTGGACCACCCCCTTTCTTCAACTCACAGTCACATGCTAACACAGGCTGAACCCTTCCCATCCCCAAC
1467 CTCAGCTTTCCTTAGAGGGGTCTGCTCTCCCGGGAGTCAGAGTAAGAGATGGCCTGCTGGGATCTGAGTC
.:J:f 1C.
TAGTGCTCTGGCCAGTTTCTGAGTGGTCATGAACTTCCCCCAGCTAACTGTGACACTTAGGGACAGGAGG1397
1117
1047
+144
+214
1327 GTAACAGATGCTGTTGGCAGAGGTGGCCAGAGAGAAGTCTTCCATCATGCCCCTCATTCCAGCAGCT
GACTGGCTTGCTGGTGCAGCCTAGCCTGGCTTCCTGAGCAGGTCTCCACTCCCTGCCCTGGCCTTTCTGT
_1:1-1257
1187 TTCTTCCAAGGATGGTCTCTTACCTCTCTTTCTGATGACTAGTCCAGGAAGGTCACCTTCTTTGACCCCA:h1:.
977
CCCAGGTGAGGCAGGGCCTCTTAGGACTCTTGTATCTATTTATAGCACCCCACATGGAGTCTGTGATCCC
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TGGGCTGTTTGTCAAGTTCTCTGACTAACCCATTAACTCCTCCTGTTTGAGGGCCTTGTCTGAGTCACC
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CTGGTGCCCAAGAGCCTGGCACGGGACTAGTCACTTTACCCATGTCTGTGGCATGCTTTTCCTACTTCCT
907 CTGTTCATTCCTTAATATTTCTTAGGCACCTACTATGTGCATGGCTCTGGGCTAAGCCTTGGGATTCAG
MEF2
-837 CAGAGGATGAGACATTCAGGATTCCTAATGGGGAGGGGCACGTGGCACGGGAGGAGGGCTGCGGTAGAA
TCATATGCAAGCCAGGCATTCGGGGCCTGAGTGTTGGCCAGAGAGCTAAGACTTACTCCAGCTCCGAC
TGACTCCTTGACCTTGTGCTTCTTGCCCTCACTAGACCTGACTTTCCAATCGACCCCAGAGATTCCTGGT
767
697
627 TAGTGTGAGGACAGAGGCTCAGCGACCGACGGCCGAGATGGAACCCCAGTCAAGGCTGGCAAGGTATT
-557 TCAGTGTTTGGAATGACACTTTGTTTAATCGGAGACTACTCCCCAGCCCGGAGAGTGGAGCTGCTATAAT
i1:i
-487 GTTACAACCAGTTACTTTGTCACTAGGCAAGGTTAGCCACTGAATTCCCCGCTCCCTAGGTGCTGGCGT
417 GCCAGGTGCTTGTAGAGGCTGGACTTAACGCGTGCTCGTTCAGCAGGCGCAGTAACTCTTTCCCACA
347 GTCGGTGAACACTCACCTGGCACGCGCCCGCCGTGGGATCGCTCTTTTCCTGCTGCCCTAGGAGGCAAGC
277 CGGTGGTCGCCGCTCTCTTCAGGGGAGCACATGGACGCTCATCCTCGGTATGGCTCAGCCATTTAGGAGT
207 CTAGTCTCACTCAGGGAACACTTTTAACCCCACGGAGCACATCGGCCCTGCCCTGCCCCCCTAGAGATCT
137 TGGGATTTTCCAGATTGCGACCCGCACACGCTGTGCCATAGGGGGGCACAGGCTGGGGCACCCAGGACCA
CGCCAGCACAATCCCCCGAGTGGGTAGGGCAGTCATCTAGACGGCAAGAGGGCGGAGCCGAGCTGTACTA
Em 
AGGGGAAGCTGGTTGGATTCCGGCTCTTGGAGGGTGGGGTTTGTGCGTGACAGTCCGGGCGGCGTCTGm! Em 
ATAGGCTGGGGCCTTTTCAGGCGGGCCAATCAGTACGATGGGCGGGGCCTGCGTGGCGCCGTCGGCAGGCEm Em Em 
GTCCGGCGCTGCCCAGTGTGGCTTTGGCGCCGCCCGCCTCGGACGCTTGGAACCGTCGCGTCTGTGTCGC
_1:1
-67
+74
+284 . GCTGTCCTCTAGATTAGTGCTCTCCGCCGCGACGGTCCGCAGCATG
CTGTCGCCCATCGCCTGCCGCCGCTGCCAGCCACCAGCAGCCATGAGCGCGCCCGGCCCCGGTGTAGTCT
? '
Figure 2. k k 3 gene 5' flanking region: Potential transcriptional
regulatory elements.
3404 bp of 5' flanking sequence of the mkk3 gene was searched for cis-acting
transcriptional elements with the program FindPatterns (GCG) using the TFSITE
database as the pattern.dat file. Illustrated are 1611 bp of sequence indicated to
be important for regulation of MKK3 expression (see Fig. 2.8). Potential
transcription factor binding sites are indicated by black boxes with white text just
below the sequence. Transcription start sites are indicated with arrows. The
major transcription start site is indicated with a heavy arrow and in designated
+ 1. The translation initiation codon is ilustrated in bold text.
"..
.c.
Figure 2.6. Regulation of MKK3 expression by MyoD in 1 OT1/2 fibroblasts.
10T1/2 fibroblasts were cultured and subjected to in vitro differentiation as
described in Materials and Methods. Luciferase assays were performed on cells
transfected with (A) MyoD and E12 or with (B) 
MEF2 expression plasm ids. A B-
galactosidase expression plasmid (pCH11 0, Pharmacia LKB) was used to control
for transfection efficiency
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MyoD-stimulated expression of 
mkk3. This may occur by activation of
endogenous MEF2 proteins or by direct activation of MyoD by the p38 MAP
kinase signaling pathway.
Next, the minimal region of the MKK3b promoter required for activation by
MyoD, MEF2C and MKK6(glu) was determined. Deletions of the 3.4 kb murine
mkk3 flanking region were made by deleting successive E-box motifs (Fig.
8). The 1 OT1/2 fibroblasts were transfected with each reporter plasmid without
or with expression plasmids for MyoD , E12 , MKK6(glu), and MEF2C. Luciferase
activity was measured as previously described. Each successive 5' deletion
resulted in a loss of basal and stimulated promoter activity. A deletion to -950 bp
of the transcription start site resulted in 22% of basal promoter activity (pGLUC-
MKK3. 8) (Fig. 2.8). However, MyoD can still stimulate luciferase expression from
this promoter fragment. In addition , MyoD stimulated expression from this
promoter fragment was stil enhanced by co-expression with MKK6(glu) (Fig 2.8).
Deleting an additional 160 nucleotides of promoter sequences from pGLUC-
MKK3.8 (pGLUC-MKK3.8b) corresponding to the removal of an extended MEF2
binding site and a consensus E-box had little effect on basal or MyoD , MEF2 or
MKK6(glu) stimulated promoter activity (Fig. 2.8). A deletion to -444 bp of the
transcription start site (pGLUC-MKK3.9) reduced the basal promoter activity to
7% and MyoD stimulated activity was also greatly diminished (Fig. 2.8). These
data define a region required for MyoD/E12 regulation of murine MKK3b
expression. These observations suggest that MEF2 binding sites may not be
required for MyoD stimulation of mkk3 expression and define region from -950 to
444 of the murine mkk35 flanking region required for response to MyoD/E12
and the p38 MAP kinase signaling pathway.
Figure 2.7. The p38 MAP kinase signaling pathway stimulates MyoD
induced MKK3 expression in 10T1/2 fibroblasts.
1 OT1 /2 fibroblasts were cultured and subjected to in vitro differentiation as
described in Materials and Methods. Cells were transfected with MyoD and E12
(A) without or with MKK6(glu), treated with DMSO (control) or SB203580
immediately prior to differentiation or (B) without or with MKK5(glu) and Erk5
and assayed for luciferase and B-galactosidase activity.
Control
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Figure 2.8. Deletion analysis of the murine mkk3 promoter.
The structure of the mkk3-reporter plasmid pGLUC-MKK3.5 is indicated. In the
top illustration MyoD binding sites / E-boxes are indicated by vertical lines and
are labeled. MEF2 sites are indicated by lines above and below the top
illustration and are also labeled. Additional transcription factor binding sites are
indicated in the bottom illustration. 10T1/2 fibroblasts were cultured and
subjected to in vitro differentiation as described in Materials and Methods. Cells
were transfected with MyoD and E12 and mkk3-reporter plasm ids without or with
MKK6 (glu) and MEF2C expression plasmids. Cell extracts were assayed for
luciferase and B-galactosidase activity as previously described in Materials and
Methods.
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Discussion
Chromosomal localization of the mkk3 ene. Sequencing of the human and
mouse genomes identified the mkk3, mkk4, mkk6 and mkk7 genes in both
species. FISH analysis has mapped the murine mkk genes to the following
chromosomal loci: mkk3, chromosome 11 region B1.3 (this study); mkk4,
chromosome 11 region B1. 3 (Mouse Genome Database, Jackson Labs); mkk6,
chromosome 11 region E1 (Tanaka et aI., unpublished observation); and mkk7
chromosome 11 region A2 (207). These cytogenetic loci on mouse chromosome
11 are syntenic to human chromosome 17. In fact , human data map the mkk3,
mkk4 and mkk6 genes to the following cytogenetic loci: mkk3, 17q11.2 (163);
mkk4, 17p11. 2 (Mouse Genome Database, Jackson Labs); and mkk6, 17q23.
q24.2 (163). These data show that the mkk3, mkk4, mkk6 and mkk7 are linked
on mouse chromosome 11 and that this genomic organization is conserved in
humans. It is interesting that mkk3 and mkk4 located less than 1 centimorgan
(cM) apart on mouse chromosome 11. The significance of this observation
remains to be tested.
Genomic or anization and ex ression of the 
mkk3 ene. The p38 MAP
kinase group consists of four isoforms: p38a; 
p38B; p38y; and p388 (27 , 38, 44
53, 59, 81, 82, 100, 103, 122 , 170, 187
214). p38 MAP kinases are activated by dual
phosphorylation on threonine and tyrosine by MKK3, MKK4
, and MKK6 (25, 27
31, 53, , 132, 133, 162, 186). While MKK4 also activates the JNK group of MAP
kinases, MKK3 and MKK6 are specific for p38 
MAP kinases(31). MKK3 and
MKK6 selectively activate the various p38 MAP kinase 
isoforms. MKK3a
activates p38a, p38yand p388 whereas MKK6 
activates all four p38 MAP kinase
isoforms (38). MKK3b contains an additional 29 amino acids in the NH2-
terminal
region compared to MKK3a and also activates all four p38 MAP kinase isoforms
(37, 61, 133). Comparison of human MKK3a, human MKK3b and murine MKK3b
cDNA revealed that the 5' UTR of MKK3a is identical to part of the 
coding
sequence of MKK3b (Fig. 2. 1a). One exception is that the translation initiation
codon (ATG) is not conserved but rather is a valine (GTG) codon in 
murine
MKK3 (Fig. 2. 1b). Sequence identity between MKK3a and MKK3b extends for
39 bp upstream of the putative translation initiation codon and encodes 13 amino
acids of the MKK3b NH2-terminal region (Fig. 2. 1 b). Exon 1 of the murine 
mkk3
gen(3 encodes the extreme 5' terminus of MKK3b and these 
sequences are
conserved in the human 
mkk3 gene. These observations strongly suggest that
MKK3b is the primary isoform of MKK3 in the mouse and that human MKK3a and
b are expressed from different promoters.
One potential means of regulation for the p38 MAP kinase pathway is at
the level of transcription. It has been shown previously that MKK3 is expressed
in many tissues but is enriched in skeletal muscle (31 61). The work presented
here demonstrates that the promoter governing MKK3b expression contains
elements implicated in muscle specific expression. These cis-acting sequence
elements confer muscle specific regulation of a luciferase reporter in an 
in vitro
muscle differentiation system. These results explain , at least partially, the
mechanism for robust MKK3b expression in skeletal muscle. The observation
that mkk3(-
/-) 
mice develop normally and have no obvious developmental defects
indicates that the product of the mkk3 gene was not required for muscle
development. The presence of sequence elements not necessary for muscle
specific expression raises the possibility that MKK3 expression may be regulated
in other cellular contexts. This in turn may provide a mechanism for the
regulation of p38 activation through the tissue specific regulation of MKK3 and
MKK6 expression. Indeed such a case has been reported for the JNK MAP
kinase activators MKK4 and MKK7 (223).
CHAPTER II
REQUIREMENT OF MITOGEN ACTIVATED PROTEIN KINASE KINASE 3
(MKK3) FOR TNF-a-INDUCED CYTOKINE EXPRESSION
Abstract
The p38 MAP kinase is activated by treatment of cells with cytokines and
exposure to environmental stress. The effects of these stimuli on p38 MAP
kinase are mediated by the MAP kinase kinases (MKK) MKK3, MKK4 and MKK6.
The function of the p38 MAP kinase signaling pathway has been examined by
investigating the effect of targeted disruption of the mkk3 gene. These data
demonstrate that mkk3 gene disruption caused a selective defect in the response
of fibroblasts to the proinflammatory cytokine TNF-a, including reduced p38 MAP
kinase activation and cytokine and chemokine expression. These data
demonstrate that the MKK3 protein kinase is a critical component of a TNFa-
stimulated signaling pathway that causes increased expression of inflammatory
cytokines and B-chemokines.
Introduction
Functional analysis of the role of the p38 MAP kinase signaling pathway
has been facilitated by the identification of pyridinyl imidazole derivatives that
inhibit p38 MAP kinase (100, 101). This inhibition is mediated by specific
interactions between the drug molecule and the A TP-binding site on the p38
MAP kinase (206 , 230, 249). Interestingly, these drugs exert anti- inflammatory
effects because they inhibit the expression of cytokines , including IL- 1, IL-6 and
TNF (100, 101). Based on this observation it has been proposed that the p38
MAP signaling pathway is a physiologically important mediator of increased
cytokine biosynthesis in response to the exposure of cells to stress (100, 101).
The p38 MAP kinase therefore represents a possible target for the design of
novel anti-inflammatory drugs.
Many studies of the p38 MAP kinase signaling pathway have relied
extensively on the use of pyridinyl imidazole drugs to inhibit the function of p38
MAP kinase in vivo. An alternative approach to studying the p38 MAP kinase
signaling pathway would be desirable because the drugs employed would inhibit
other protein kinases under some experimental conditions (20, 38 , 39, 81 , 228).
The need for an alternative approach to complement pharmacological studies
was highlighted by the recent finding that pyridinyl imidazole drugs , including
SB203580 directly inhibit thromboxane synthase and cyclooxygenase-1 and
cyclooxygenase-2 (13). This observation indicates that some of the actions of
the p38 MAP kinase inhibitors may be secondary to changes in prostaglandin
metabolism that occur independently of p38 MAP kinase inhibition.
The genetically tractable model organism Drosophila is likely to be useful
for studies of the functional role of the p38 MAP kinase signaling pathway (63).
Similar genetic analysis in mammals is difficult. However, targeted gene
disruption strategies can be employed to study the function of signaling pathways
in mice. Because there are four genes that encode p38 MAP kinases in
mammals (27 , 38 , 53 , 81 , 82, 103 , 187 , 214), which may have partially redundant
functions, we have investigated the effect of targeted disruption of the genes that
encode MKK that activate the p38 MAP kinase. Three genes have been
identified: Mkk3 (31), mkk4 (31 , 104), and mkk6 (60, 132, 162, 186). The MKK3
and MKK6 protein kinases are specific for p38 MAP kinase whereas the MKK4
protein kinase can activate both p38 MAP kinase and JNK. Disruption of the
mkk4 gene causes marked defects in JNK activation and early embryonic death
(46 , 149 , 241). Mkk4 /-) cells therefore do not provide a good model for studies
of p38 MAP kinase signaling. However, it was likely that the disruption of a gene
that encodes a specific activator of p38 MAP kinase might cause a selective
defect in p38 MAP kinase signaling. The studies presented here examine the
effect of targeted disruption of the mkk3 gene on the p38 MAP kinase signaling
pathway in murine embryo fibroblasts.
Experimental Procedures
Tar eted Disru tion of the mkk3 ene. DNA clones corresponding to the
mkk3 locus were cloned from a AFix II phage library prepared from genomic DNA
isolated from mouse strain 129/sv (Stratagene). Positive clones were
characterized by Southern blot analysis and DNA sequencing (Applied
Biosystems). The PGK-neo cassette and herpes simplex (HSV)-thymidine kinase
gene vector pBSNTK2 was constructed as previously described (241). A 4.4-
8glll- Bg/lI fragment from the 5' end of the mkk3 genomic clone was excised
with Not I and Spe I, and ligated into the Not I and Xba 
I sites of pBSNTK2.
Finally, a 0.92- kb Eco RV- Hinc II fragment derived from the 3' end of the mkk3
gene was inserted into the vector at the Xho I site using 
Xho I linkers. The
resulting targeting vector was linearized with Not I and electroporated into W9.
embryonic stem cells. Genomic DNA from transfectants resistant to G418 (0.
mg/ml) (Life Technologies, Gaithersburg, MD) and gancyclovir (2 J.M) (Syntex,
Palo Alto, CA) was isolated and screened by Southern blot analysis. The probe
used was a 240- bp fragment of the mkk3 genomic sequence external to the
targeting construct that hybridizes to a 20-kb Eco RI fragment of the endogenous
mkk3 gene and to a 7-kb fragment of the targeted allele. Heterozygous mkk3 
/+) cells were injected into C57BU6 blastocysts to create chimeric mice, which
were crossed to obtain germ-line transmission of the disrupted mkk3 allele.
Heterozygous mkk3 /+) mice were intercrossed to obtain wild type mkk3 
(+/+)
and mutant mkk3 /-) mice.
Characterization of mkk3 mice. Genomic DNA was isolated from mouse
tails, digested with Eco , and subjected to Southern Blot analysis as described
above. Northern blot analysis was carried out by isolating total RNA from kidney
and liver using the TRlzol reagent and hybridized to a RT-PCR fragment
corresponding to nucleotides 777- 1231 of the MKK3 cDNA.
Pre aration of murine embr o fibroblasts. Embryonic day 14 mkk3 /-) and
wild type embryos were employed to prepare murine embryo fibroblasts (MEF).
The cells were grown in DMEM supplemented with 10% heat- inactivated FBS/2
mM glutamine/100 units/ml penicilin/100 J.g/ml of streptomycin (Life Technologies)
at 37 in a humidified atmosphere of 5% CO Control experiments
demonstrated that the wild type (+/+) and mkk3 /-) MEF proliferated at similar
rates. The cells were treated with 10 J.M SB203580 (Calbiochem), 10 ng/ml TNF-
a (Genzyme), 10 ng/mIIL- 1 B (Genzyme), 300 mM sorbitol , or 40 J/m2 UV radiation
(UV-C).
Immuno reci itation. Cells were solubilized with lysis buffer (20 mM Tris, pH
704/ 1% Triton X- 100/ 10% glycerol/ 137 mM NaCI/ 2 mM EDTA/ 25 mM 
glycerophosphate/1 mM Na orthovanadate/ 2 mM pyrophosphate/ 1 mM phenyl-
methylsulfonylfluoride/ 10 J.g/ml leupeptin) and centrifuged at 14000-x g for 15
minutes at 4 C. Protein kinases were immunoprecipitated by incubation with
polyclonal antibodies to JNK or p38 MAP kinases bound to protein-A Sepharose
(Pharmacia-LKB) .
Protein kinase assa s. Protein kinase assays were performed in kinase buffer
(25 mM 4-(2-hyroxyethyl)- piperazineethanesulfonic acid , pH 704/ 25 mM 
glycerophosphate/ 25 mM MgCI / 2 mM dithiothreitol/ 0. 1 mM orthovanadate).
Immunoprecipitates were washed twice with lysis buffer and twice with kinase
buffer. The assays were initiated by the addition of 0.5 J.g substrate proteins and
50 f.M (y- 32 p)A TP (10 Ci/ mMol; 1 Ci = 37 GBq) in a final volume of 25 J.1. The
reactions were terminated after 30 minutes at 30 C by the addition of Laemmli
sample buffer. The phosphorylation of the substrate proteins was examined after
SDS-PAGE by autoradiography and Phosphorimager analysis.
tokine ELISA. IL- Band IL-6 were measured with a kit , using procedures
recommended by the manufacturer. Cells were treated with TNF-a for 24 hours
in vitro and culture medium harvested for IL-6 ELISA. IL- 1 B ELISA was
performed on cells solubilized in lysis buffer.
RNase rotection assa
y (
RPA MEF were treated with TNF-a in vitro for six
hours and total RNA was isolated using RNA-Stat reagent (TeITest). RPA was
performed using 10 Jlg total RNA under conditions suggested by the
manufacturer. The RiboQuant RPA kit was purchased from Pharmingen (San
Diego , CA). Probe sets mCK- , mCK-3b, mCR-4 and mCK-5 were used to
detect mRNA expression. Protected RNA fragments were fractionated by
denaturing PAGE (6% polyacrylamide 8M urea) and analyzed by auto-
radiography and Phosphorimager analysis.
Immunoblot anal sis. Cell Iysates (30 Jlg) were fractionated by SDS-PAGE
transferred to an Immobilon-P membrane (Millipore Inc. ) and probed with a
polyclonal antibody to p38 MAP kinase (Santa Cruz Biotechnology), a mAb to JNK
(PharMingen), and rabbit polyclonal antibodies to MKK3, MKK4 , and MKK6. The
MKK antibodies were prepared by immunizing rabbits with purified , recombinant
human protein kinases expressed in bacteria. Immunecomplexes were detected
by enhanced chemiluminescence (Amersham).
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Results
Generation of mkk3 mice. The MKK3 protein kinase was identified
previously as a specific activator of the p38 MAP kinase (31). The mkk3 gene
was isolated by screening a mouse genomic library with the human MKK3 cDNA.
Disruption of the murine mkk3 gene in W9.5 embryonic stem (ES) cells was
accomplished by replacement of mkk3 sequences with a NeoR cassette by
homologous recombination (Fig. 3. 1 a) utilizing a strategy of positive and negative
selection. A targeting vector constructed by standard techniques is shown in
Fig. 1 a. Homologous recombination with the endogenous mkk3 gene will
replace an internal 1. kb Bg/lI- EcoR V genomic fragment with a neo gene
cassette. The deleted region includes exons 8 and 9, which encode amino acids
217-221 of the murine MKK3 protein. This region includes the sequence Ser-Val-
Ala-Lys-Thr containing the dual phosphorylation sites (Ser and Thr) that are
required for MKK3 activation (31). The deleted region also encompasses
sequences that are highly conserved among all protein kinases (64). These
observations led us to anticipate that the predicted targeted disruption of the
mkk3 gene would result in a null allele.
The linearized targeting construct was transfected into W9.5 ES cells.
Disruption of one mkk3 allele was confirmed by Southern blot analysis of
genomic DNA. Analysis of 159 independent G418 and gancyclovir-resistant
clones identified 14 positive clones. The frequency of homologous recombinants
among the G418 and gancyclovir-resistant clones was 9%. Chimeric mice were
created by injecting six independent clones of heterozygous mkk3 /+) stem cells
into C57BU6 blastocysts. Two clones resulted in germ line transmission of the
disrupted mkk3 allele. Heterozygotes were intercrossed to obtain homozygous
mkk3 /-), which were identified by Southern blot analysis of genomic DNA.
Crosses of the mkk3 (+/-) mice resulted in progeny with the expected Mendelian
frequencies. Northern blot analysis of kidney and liver RNA confirmed that the
homozygous mkk3 /-) mice did not express detectable levels of mkk3 mRNA
(Fig. 3. 1c). The mkk3 /-) mice were viable and fertile with no observed
developmental defects. No gross histological abnormalities of the lymphoid
organs were apparent in young mice. Gross histological analyses of
hematoxylin- and eosin-stained sections of other non- lymphoid organs, including
liver and lung, also revealed no obvious abnormalities. The absence of a
profound defect in the mkk3 /-) animals may reflect a redundant function of the
MKK3 protein kinase in the presence of the p38 MAP kinase activators MKK4
(31) Hnd MKK6 (122 , 187, 188, 214).
Figure 3. 1. Disruption of the mkk3 gene by homologous recombination.
(A) Structure of targeted vector, mkk3 gene and the mutated mkk3 gene
following homologous recombination. Relevant restriction enzyme sites are
indicated. (N: Notl; RV:EcoRV; Sm:Smal; B:BamHI; R:EcoRI; Bg:BglI; Hc:Hincll).
Exons 7 , 8 and 9 are depicted as closed boxes. SVAKT is the protein sequence
(single letter code) encoding the dual phosphorylation sites required for MKK3
activation. The diagnostic probe used for Southern analysis is illustrated.
(B). Southern blot analysis. Genomic DNA from mouse tails was digested with
EcoRI , and blots were hybridized with the probe shown in (A). The wild-type
allele corresponds to a 20-kb fragment and the mutated allele is a 7 -kb fragment.
(C). Northern blot analysis. Total RNA isolated from kidneys and livers of wild-
type and homozygous mice was hybridized with a MKK3 cDNA fragment. The
blots were also probed for B-actin mRNA which was used as an internal control.
(D). Western blot analysis. Protein Iysates from primary mouse embryo
fibroblasts (MEF) of wild-type and homozygous mice were used to examine the
expression of MKK3, MKK4 , MKK6, JNK and p38 MAP kinase.
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Biochemical analysis of the effect of mkk3 gene disruption was facilitated
by the preparation of primary MEF. Protein immunoblot analysis of extracts
prepared from wild type (+/+) and mkk3 /-) MEF demonstrated that, in contrast
to wild type cells, the mkk3 /-) cells do not express the MKK3 protein kinase
(Fig. 1d). However, both wild type (+/+) and mkk3 /-) cells express similar
levels of the stress-activated MKK MKK4 and MKK6 (Fig. 3. 1 d). These data
demonstrate that the mkk3 gene disruption caused a selective defect in the
expression of the protein kinase MKK3 in the absence of changes in the
expression of the other stress-activated MKK. In addition , the mkk3 gene
disruption caused no change in the expression of the stress-activated MAP
kinases p38 and JNK (Fig. 3. 1 d).
The loss of MKK3 was predicted to cause defects in the p38 MAP kinase
signaling pathway. Studies were therefore performed to examine the regulation
of p38 MAP kinase in wild-type (+/+) and mkk3 /-) MEF. The basal activity of
p38 MAP kinase was reduced slightly (approximately 40% lower) in mkk3 
/-)
MEF compared with wild-type (+/+) MEF). Exposure to environmental stress (UV
radiation and osmotic shock) and the inflammatory cytokine IL-1 caused
activation of p38 MAP kinase in both wild-type (+/+) and mkk3 /-) MEF (Fig.
2a). These stimuli also caused similar activation of the stress-activated JNK
MAP kinase in wild-type (+/+) and mkk3 /-) MEF (Fig. 3.2a). In contrast , studies
of the effect of TNF-a demonstrated that the mkk3 /-) were selectively defective
in the activation of p38 MAP kinase (Fig. 3.2b).
The defect in TNF-a-stimulated p38 MAP kinase activity observed in mkk3
/-) MEF might reflect a general deficiency of these cells in their response to
TNF-a signaling. However, ribonuclease protection assays demonstrated that
the expression of the p55 and p75 TNF receptors was equal in wild-type (+/+)
and mkk3 /-) MEF. This observation suggested that the mkk3 /-) MEF may
have a selective defect in their response to TNF-a. To test this hypothesis the
effect of TNF-a on the stress-activated MAP kinase JNK was examined. These
data demonstrated that TNF-a caused similar JNK activation in wild-type (+/+)
and mkk3 /-) MEF (Fig. 3.2b). These observations demonstrated that the
defect in p38 MAP kinase activation in mkk3 /-) MEF represents a selective
impairment of TNF-a signaling to the p38 MAP kinase pathway. The conclusion
from these studies is that the MKK3 protein kinase is required for efficient TNF-a-
stimulated p38 MAP kinase activation in MEF.
The stress-activated p38 MAP kinase signaling pathway has been
implicated as a regulatory mechanism that controls the production of cytokines
Figure 3. 2. Effect of mkk3 gene disruption on stress-activated MAP kinase
activity in MEF.
(A) Wild-type (+/+) and MKK3 (-/-) MEF were untreated , or treated with UV-C (80
J/m ), osmotic shock (300 mM sorbitol , 30 min. ), or IL- 1 (10 ng/ml , 15 min). (B)
Wild-type (+/+) and MKK3 (-/-) MEF were untreated or treated with TNF-a (10
ng/ml). The cells were harvested at the indicated times. The p38 MAP kinase
and JNK activity were measured using an immunecomplex kinase assay with the
substrates ATF2 and c-Jun , respectively (161). Radioactivity incorporated into
each substrate was quantitated after SDS-PAGE by Phosphorimager analysis.
The data are presented as the relative protein kinase activity.
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by cells exposed to stress. Previous studies have established that p38 MAP
kinase may mediate the effect of TNF-a to induce the expression of IL- 1 (239)
and IL-6 (228). I therefore examined cytokine expression by wild-type (+/+) and
mkk3 /-) MEF treated with TNF-a. Treatment of wild-type (+/+) MEF with TNF-
a increased the production of IL- 1 and IL-6 (Fig 3.3). The p38 MAP kinase
inhibitor SB203580 (158) partially inhibited TNF-a stimulated IL- 1 and IL-
synthesis (Fig. 3.3a-b). In contrast , disruption of the mkk3 gene markedly
decreased the TNF-a stimulated production of IL- 1 and IL-6 by MEF (Fig. 3.3a-
b). These data demonstrate that mkk3 gene disruption caused a defect in TNF-
a-stimulated IL-1 and IL-6 expression , indicating that the MKK3 protein kinase is
an essential component of the TNF signaling pathway that regulates cytokine
expression.
The induction of cytokine expression caused by TNF-a may be mediated
through the regulation of several steps in the cytokine biosynthetic pathway,
including increased mRNA expression and increased mRNA translation (32, 228
239). The defect in cytokine expression by mkk3 /-) MEF therefore may result
from alterations in either of these processes. To examine the mechanism that
accounted for the defective production of cytokines by mkk3 /-) MEF the ability
of TNF-a to induce cytokine mRNA expression was measured by ribonuclease
Figure 3. 3. Effect of mkk3 gene disruption on IL-1 and IL-6 production in
MEF.
Wild-type (+/+) and MKK3 (-/-) MEF were untreated , or treated with SB203850
(10 /lM) for 2 hours and subsequently treated with TNF-a (10 ng/ml). A) Cell
Iysates were made at the indicated times and IL- 1 was measured by ELISA. (B).
Culture medium was collected at the indicated times and IL-6 was measured by
ELISA.
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protection assay. Control experiments demonstrated that the amount of
glyceraldehyde- phosphate dehydrogenase (GAPDH) mRNA detected in wild-
type (+/+) and mkk3 /-) MEF was similar and treatment with TNF-a did not
cause marked changes in the amount of GAPDH mRNA. In contrast, treatment
of wild-type (+/+) MEF with TNF-a increased the amount of IL- , IL-6 and TNF-a
mRNA (Fig 3.4). The mkk3 /-) MEF were defective in the TNF-a stimulated
accumulation of IL- 1, IL-6 and TNF-a mRNA (Fig 3.4). This defect in cytokine
expression was selective because TNF-a did induce the expression of TCA3
chemokine mRNA to a similar extent in wild-type (+/+) MEF (14-fold) and mkk3 
/-) 
MEF (15-fold). These data demonstrate that the mkk3 
/-) 
MEF were
selectively defective in TNF-a induced expression of IL- , IL-6, and TNF-a
mRNA.
Chemokines are a class of soluble inflammatory mediators that control
leukocyte function and trafficking (169). C-C chemokines (or B-chemokines) are
a subclass of chemokines whose expression was induced by LPS and TNF-
a stimulation (169). Examination of chemokine expression by ribonuclease
protection assay reveals that TNF-a treatment results in increased accumulation
MIP1 a, 1 B, 2 and RANTES (regulated on activation of normal I-cells xpressed
Figure 3. 4. Effect of mkk3 gene disruption on cytokine mRNA expression.
Wild-type (+/+) and MKK3 (-/-) MEF were untreated or treated with TNF-a (10
ng/ml) for 24 hours and cytokine mRNA was measured by RPA. Radioactivity
incorporated into each protected RNA was quantitated after denaturing
polyacrylamide gel electrophoresis by Phosphorimager analysis. Control studies
demonstrated equal levels of GAPDH mRNA.
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and ecreted) f)chemokine mRNA in wild type (+/+) MEF (Fig. 3.5). In contrast,
disruption of the mkk3 gene resulted in decreased TNF-a-stimulated
accumulation of MIP1 a, 1 Band 2 mRNA by MEF (Fig. 3. 5). Surprisingly, mkk3 
/-) 
MEF exhibited markedly increased accumulation of RANTES mRNA in
response to TNF-a treatment (Fig. 3.5). TNF-a-stimulated accumulation of TCA3
B-chemokine mRNA was similar between wild type (+/+) and 
mkk3 /-) MEF (see
above). These data demonstrate that the mkk3 
/-) 
MEF were selectively
defective in TNF-a induced expression of MIP1 a, 1 Band 2 mRNA.
No defects in the expression of cytokine mRNA were detected in control
cultures of mkk3 /-) MEF treated without TNF-a (Fig. 3.4). However, increased
expression of the IL-1 receptor antagonist (IL- 1 RA) was observed in mkk3 
/-)
MEF compared to wild-type cells (Fig, 3.4e). This observation suggests that
MKK3 functions genetically to down-regulate IL- 1 RA expression. The
biochemical basis for this effect is unclear, but may be related to the altered
basal p38 MAP kinase activity in mkk3 /-) MEF. In addition mkk3 /-) MEF
over-accumulate RANTES mRNA in response to TNF-a (Fig. 3.5a). Thus, MKK3
may also function to down-regulate TNF-a-stimulated RANTES expression.
Further studies are required to test these hypotheses.
Together these data indicate that the defective cytokine expression by
mkk3 /-) MEF was accounted for, at least in part, by the failure of TNF-a to
induce the expression of cytokine mRNA (Fig. 3.4).
Figure 3. 5. Effect of mkk3 gene disruption on chemokine mRNA
expression.
Wild-type (+/+) and MKK3 (-/-) MEF were untreated or treated with TNF-a (10
ng/ml) for 24 hours and chemokine mRNA was measured by RPA. Radioactivity
incorporated into each protected RNA was quantitated after denaturing
polyacrylamide gel electrophoresis by Phosphorimager analysis. Control studies
demonstrated equal levels of GAPDH mRNA.
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Discussion
It has been proposed that the p38 MAP kinase signaling pathway is an
important mediator of inflammatory processes. Several lines of experimental
evidence support this contention. First, endotoxic lipopolysaccharide and
proinflammatory cytokines cause marked activation of p38 MAP kinase (161).
Second, specific inhibitors of p38 MAP kinase (pyridinyl imidazole drugs) inhibit
the secretion of inflammatory cytokines (100). Third, transgenic animal models
demonstrate that the p38 MAP kinase regulates transcription of the interferon-
gene by T helper 1 cells (167). The results of the present study provide further
support to the hypothesis the p38 MAP kinase signaling pathway contributes to
inflammatory processes. Disruption of the mkk3 gene, which encodes an
activator of p38 MAP kinase, caused a selective defect in TNF-a stimulated p38
MAP kinase activation (Fig. 3.2) and inflammatory cytokine expression (Figs. 3.
and 3.4). Together, these observations strongly implicate the p38 MAP kinase
pathway as a mediator of inflammatory signaling.
The conclusion that p38 MAP kinase is a mediator of inflammation in
mammals is in contrast with observations that have been reported concerning the
role of p38 MAP kinase in the innate immune response of Drosophila. Two
genes that encode p38 MAP kinase and one gene that encodes a p38 MAP
kinase activator have been identified in Drosophila by molecular cloning (63).
Inhibition of the Drosophila p38 MAP kinase signaling pathway caused increased
expression of antibacterial and antifungal genes. This observation suggested
that the p38 MAP kinase, which is activated during the innate immune response
in the fly, normally functions to down-regulate this response (63). Further studies
are required to define whether this apparent difference between mammals and
insects reflects an evolutionary change in the function of the p38 MAP kinase or
whether the different observations indicate that the role of p38 MAP kinase can
be altered in highly differentiated tissues.
Another possibility is that regulation of inflammatory cytokine expression in
mammals does not accurately reflect the innate immune response in Drosophila.
Chemokine expression is known to be modulated by the transcription factor,
NFKB. RelB (-/-) fibroblasts exhibit a persistent induction of a number of
chemokines including RANTES, MIP1a, B, and 2 in response to LPS (238). This
observation suggests that RelB functions to dampen the inflammatory response
in fibroblasts. The observation that mkk3 
/-) 
MEF exhibit a dramatic
overexpression of RANTES mRNA in response to TNF-a (Fig. 3.5) suggests that,
under some circumstances, the p38 MAP kinase pathway may also function to
dampen the inflammatory response by modulating chemokine expression. This
was consistent with the observation that mkk3 /-) MEF also over-accumulate IL-
1RA mRNA.
Mkk3 ene disru tion causes a selective defect in 38 MAP kinase
nalin . The targeted disruption of the mkk3 gene caused only a selective
defect in the p38 MAP kinase signal transduction pathway (Fig. 3.2). It was likely
that a more profound defect in p38 MAP kinase signaling was not observed
because the function of the MKK3 protein kinase is partially redundant to the
MKK4 and MKK6 protein kinases. Indeed, many studies have documented that
MKK6 is a strong activator of p38 MAP kinase (60, 162, 186). For example , MKK6
is the major activator of p38 MAP kinase in cells exposed to osmotic stress (133).
Interestingly, mkk3 /-) MEF were selectively defective in their response to TNF-
a whereas JNK activation was comparable to that observed in wild-type MEF
(Fig. 3.2). Thus, the MKK3 protein kinase was required for full activation of p38
MAP kinase in response to the treatment of MEF with TNF-a. The observation
that TNF-a does not activate MKK4 (79) can account for the lack of
complementation of the MKK3 deficiency by MKK4. In contrast , MKK6 can be
activated by TNF-a (133). The low level of p38 MAP kinase activation observed
in TNF-a treated mkk3 /-) MEF therefore may be mediated by MKK6. Further
studies of other cell types derived from the mkk3 /-) mice are warranted to
document more fully this partial complementation by MKK6.
The MKK3 rotein kinase is re uired for TNF-a re ulated c tokine and
chemokine ex ression. Studies using pyridinyl imidazole drugs, which inhibit
p38 MAP kinase, indicate that these compounds may regulate the translation of
cytokine mRNA' s (94, 100, 101 , 159). The mechanism by which the p38 MAP
kinase pathway regulates cytokine mRNA translation requires further study, but
recent progress has been achieved through the identification of cytokine-
responsive translational regulatory elements (94) and the identification of a group
of eIF-4E protein kinases that are activated by p38 MAP kinase (45, 218).
Although the effect of mkk3 gene disruption to block TNF-a stimulated
expression of IL- 1, IL-6, TNF-a and MIP1 a, 1 B, and 2 mRNA indicates that the
regulation of cytokine and chemokine mRNA expression is the primary target of
the MKK3 protein kinase signaling pathway in MEF (Fig. 3.4 , Fig 3.5), these data
do not exclude the possibility that this signaling pathway may also regulate later
steps in the cytokine and chemokine biosynthetic pathways, including translation.
It is i;lso possible that the relative importance of regulated mRNA expression and
translational regulation for TNF-a-stimulated cytokine and chemokine expression
may differ between cell types.
Previous studies have established that the p38 MAP kinase signaling
pathway mediates activation of several transcription factors , including ATF1 (78
201), ATF2 (161 , 162), CHOP (215), CREB (78 , 201), ELK1 (158 , 228), MEF2C
(58), NF-KB (212, 253) and SAP- 1 (158 , 228). Defects in the activation of one or
more of these transcription factors may contribute to the reduced TNF-a-
stimulated expression of cytokine mRNA in these cells. Indeed , treatment with
pyridinyl imidazole drugs inhibits the induction of IL-6 mRNA in TNF-a stimulated
fibroblasts (9). The biochemical mechanism that accounts for the p38 MAP
kinase-regulated expression of IL-6 mRNA may be caused by increased stability
of the IL-6 mRNA (126) or by increased transcription of the IL-6 gene mediated,
in part, by NF-KB (212). Further studies are required to identify the specific
defects that are present in mkk3 /-) MEF.
CHAPTER IV
DEFECTIVE IL- 12 PRODUCTION IN mkk3(-I-) MICE
Abstract
The p38 mitogen-activated protein kinase (MAPK) pathway, like the c-Jun
terminal kinase (JNK) MAPK pathway, is activated in response to cellular
stress and inflammation and is involved in many fundamental biological
processes. To study the role of the p38 MAP kinase pathway in vivo homologous
recombination was used to inactivate the mkk3 gene , one of the two specific
MAPK kinases (MKK) that activate p38 MAP kinase. Targeted disruption of the
mkk3 gene resulted in mice that were viable and fertile. However mkk3 
/-)
mice exhibited defects in LPS-stimulated interleukin- 12 (IL- 12) production and
CD40- ligand (CD40L) stimulated IL- 12 production by macrophages and dendritic
cells respectively. The effect of the p38 MAP kinase pathway on IL- 12 expression
was in part transcriptional since inhibition of this pathway blocks IL-12 p40
promoter activity in macrophage cell lines and IL- 12 p40 mRNA was reduced in
mkk3 /-) mice. Interferon (IFN)-y production following immunization with protein
antigens and in vitro differentiation of naive T cells are greatly reduced in mkk3 
/-) mice, suggesting an impaired type- 1 cytokine immune response. The
conclusion drawn from these studies is that the p38 MAP kinase , activated
through MKK3, is required for the production of inflammatory cytokines by both
antigen-presenting cells and CD4+ T cells.
Introduction
LPS is a cell wall component of Gram-positive bacteria that induces
pathologic responses including inflammation and sepsis (213). Induction of the
inflammatory response is due in part to the activation of the transcription factors
NFKb and AP-1 that regulate expression of pro-inflammatory cytokines (21 , 33
164, 178 , 210). Recent reports have identified AP-1 and NFKB as targets of the
p38 MAP kinase signaling pathway in response to LPS (reviewed in chapter 1).
Activation of the p38 MAP kinase signaling pathway by LPS stimulates
expression of the inflammatory cytokines IL- 1 and TNF-a by monocytes and
macrophages (25 , 27 , 146). In contrast, treatment of cells with the p38 inhibitor
SB203580 blocks LPS-stimulated cytokine expression (100, 101 , 159). These
observations implicate the p38 MAP kinase signaling pathway as an important
mediator of the inflammatory response.
Accumulating evidence also implicates the p38 MAP kinase pathway in
mediating cellular responses to the TNF family member CD40L (101, (54, 190).
Exposure of antigen presenting cells (APC) to CD40L activates pathways
culminating in the expression of inflammatory cytokines, most notably IL- 12 (18
, 85 , 90). CD40L-stimulated APC, especially dendrite cells (DC) are an
important source of IL- 12 which is essential for mediating differentiation of naive
CD4+ T-cells into T H 1 cells and stimulates production of IFN-y (1 49, 151
168, 231). Genetic studies identify the p38 MAP kinase pathway as an important
mediator of the T H1 specific cytotoxic immune response (167). Transgenic mice
expressing dominant negative p38 MAP kinase exhibit specific impairments in
the production of IFN-y by T H 1 cells (29) In contrast, activation of the p38 MAP
kinase pathway by expression of constitutively active MKK6 resulted in
exacerbated T H 1 responses (167).
The specific upstream MAPK kinases for p38 MAPK are MKK3 and MKK6
(25 , 31 , 58 , 60, 132 , 133 , 162, 186), although MKK4 , an upstream kinase for JNK
has also been implicated in the activation of the p38 MAPK pathway (31 , 104).
The studies presented here examine the effect of targeted disruption of the 
mkk3
gene on the p38 MAP kinase signaling pathway during inflammatory and type-
cytokine responses. MKK3-deficient mice are viable and fertile. Nevertheless,
these mice have defective p38 MAPK activation and defects in the production of
IL-12 and IFN-y, resulting in impaired T H1 CD4+ immune response. These
results suggest that MKK3 activates the p38 MAPK signaling pathway in
response to LPS and during a T H 1 immune response.
Experimental Procedures
Rea ents. LPS (E. coli strain 0127:B8), Concanavalin A (Con A), G418 and
Keyhole limpet hemocyanin (KLH) were purchased from Sigma Chemical Co.
(St. Louis , MO). Complete Freund's adjuvant (CFA) was purchased from Life
Technologies , Inc. (Gaithersburg, MD). Gancyclovir was purchased from Syntex
(Palo Alto , CA). Sorbitol was purchased from Sigma (St. Louis , MO). The p38
inhibitors SB 203580 and SB 202190 and the control chemical SB 202474 were
purchased from Calbiochem-Novabiochem Corp. (La Jolla, CA). Brewer
thioglycollate was purchased from Difco (Detroit, MI). The GM-CSF-producing
hybridoma was kindly provided by Dr. David Gray (Royal Postgraduate Hospital
London). The membrane-bound CD40L was kindly provided by Dr. Marilyn Kehry
(Boehringer- Ingelheim , Danbury, CT). Human recombinant IL-2 was kindly
provided by Biogen Inc.. Murine IL-12 was kindly provided by Genetks Institute.
CD44-biotin, CD45RB-FITC antibodies and Streptavidin-PE were purchased
from Pharmingen (San Diego, CA).
Plasmids. The I L- 12 p40 promoter reporter plasmid , kindly provided by Dr.
Steve Smale (UCLA), contains the -350 to +50 region of the p40 promoter-driving
a firefly luciferase gene (156). The PRL- SV40 Renila luciferase plasmid was
purchased from Promega (Madison , WI). MKK3(ala) and p38(agf), dominant
negative constructs for MKK3 and p38 respectively, MKK3(glu) and MKK6(glu),
constitutive active constructs of MKK3 and MKK6 respectively, and p38a, p38B,
p38y and p38b expression constructs were previously described (38, 162). All
plasmid DNA was isolated by using Endotoxin-free Maxi-prep kit (Qiagen Inc.
Valencia, CA).
Isolation and culture of eritoneal macro es. 5-6 weeks old mice were
injected with 3 ml of 3% Brewer thioglycollate Lp. and 72 hours later, peritoneal
exudate cells (PECs) were isolated from the peritoneum. The thioglycollate-
elicited PECs were cultured at 37 C and 5% CO in 48-well plates at 5 x 105
cells/well in 1 ml/well of high-glucose DMEM (Gibco BRL, Gaithersburg, MD)
supplemented with 10% FBS (Hyclone, Logan , UT), 2 mM L-glutamine, and
penicillin/streptomycin. Two hours later, non-adherent cells were removed and
the adherent macro phages were subjected to various treatments. Peritoneal
macrophages were treated with LPS (100 ng/ml) for different times, the
supernatants were collected and immediately analyzed for cytokine production by
ELISA. For analysis of IL-1a and B production, the macrophages were treated
with LPS for 4 hr, ATP (5 mM) was then added into the culture for an additional
30 min to release IL- 1 into the media (68). The supernatants were collected for
ELISA.
Measurement of MKK3 and 38 MAP kinase activit
. p38 MAP kinase activity
in cell Iysates was measured using jmmunecomplex kinase assays (161). The
activity of MKK3 was measured in transfected cultured macrophages. RAW264.
cells were grown in DMEM (Gibco-BRL, Gaithersburg, MD) supplemented with
5% FBS (Hyclone Inc. , Logan , UT), 2 mM L-glutamine, and antibiotics
(penicillin/streptomycin). Flag-tagged MKK3 was expressed by transfection of 2 x
cells using the Superfect reagent (Qiagen Inc., Valencia, CA). After
transfection (3 hrs), the cells were divided into two groups and incubated for 24
hrs. The cells were treated (30 min. ) without or with LPS (1 g/ml). Ceillysates
were prepared and MKK3 was isolated by immunoprecipitation using the M2
monoclonal antibody to the Flag epitope (Sigma). MKK3 protein kinase activity
was measured in the immunoprecipitates in a coupled kinase assay (30 min.
C) using 0. g GST-p38y, 0. g GST-ATF2 , and 50 M (y- P)ATP. The
phosphorylation of A TF2 was quantitated following SDS-PAGE by
Phosphorimager analysis (Molecular Dynamics Inc.
RNase rotection assa
y (
RPA . Peritoneal macrophages were treated with
LPS in vitro for various times and total RNA was isolated using TRlzol reagent
(Gibco BRL , Gaithersburg, MD). RPA was performed using 5 g total RNA under
conditions suggested by the manufacturer. The RiboQuant RPA kit was
purchased from Pharmingen (San Diego , CA). Probe sets mCK-2b and mCK-
were used to detect cytokine expression. Normalization was calculated by
determination of the ratio of individual cytokine mRNA against GAPDH mRNA on
a phosphorlmager screen. The percent inhibition was determined by the
following formula:
percent inhibition (%) = 100 X H+/+ cytokine:GAPDH) - (-/- cytokine:GAPDH)) /
(+/+ cytokine:GAPDH).
Isolation and culture of bone marrow-derived dendritic cells. Bone marrow
cells were isolated from the femur and tibia of male mice of 6-8 weeks of age as
described (155). The cells were treated with a combination of depleting
antibodies (anti-B220 , anti-MHC class II , anti-CD4 and anti-CD8) and
complement for 1 hr at 37 C (257). The remaining live cells were cultured at 1 X
6 cells/ml in 2 ml/well RPMI supplemented with 5%FCS and GM-CSF (666
U/ml) in a 24-well plate. The culture medium was changed every two days to
remove non-adherent granulocytes. On day 8, cells in suspension were collected
replated and subjected to various treatments. Bone marrow-derived dendritic
cells were treated with membrane-bound CD40L for 48 hr, the supernatants were
collected and subjected to ELISA analysis for cytokine production.
Enz me- linked immunosorbent assa
y (
ELISA . The ELISA was performed as
previously described (167). Mouse ELISA paired antibodies for TNF-a, IL-6, IFN-
and IL-4 were purchased from Pharmingen (San Diego, CA). A mouse IL-
ELISA kit was purchased from Biosource International (Camarillo, CA), which
detects the mature IL- 12 p70 heterodimer. Mouse IL- 1a ELISA kit was purchased
from Endogen (Cambridge, MA), The mouse IL- 1 B DuosetTM paired antibodies
and mouse IL- 1 B standard were purchased from Genzyme (Cambridge , MA).
The concentration of the coating antibody for TNF-a and IL-6 was 4 J1g/ml and
the secondary biotinylated antibody was 2 J1g/ml. The concentration of the
coating antibody used for -I' and IL-4 was 0.625 J1g/ml and 1 J1g/ml respectively
and the secondary biotinylated antibody was 2 J1g/ml and 1 J1g/ml respectively.
The ELISA for IL- 12, IL-1a and IL-1B was performed according to the
manufacturer s instructions. Mouse IL-6 and TNF-a (R&D Systems , Minneapolis,
MN), IFN-I' (Gibco BRL, Gaithersburg, MD) and IL-4 (DNAX, Los Angeles, CA)
were used as standards. Horseradish peroxidase-conjugated avidin D was
purchased from Vector Laboratories (Burlingame , CA). The TMB microwell
peroxidase substrate and stop solution were purchased from Kirkegaard and
Perry Laboratories (Gaithersburg, MD).
Measurement of IL- 12 40 romoter-driven luciferase activit The
RAW264.7 murine macrophage line was grown in DMEM (Gibco BRL
Gaithersburg, MD) supplemented with 5% FBS (Hyclone , Logan, UT), 2 mM L-
glutamine, and penicilin and streptomycin. 2X10 cells/well in 6-well plate was
transiently transfected by Superfect (Qiagen Inc. , Valencia, CA) according to
manufacturer s protocol with 4 J.g of IL-12 p40 promoter-driven firefly luciferase
reporter plasmid and 0.4 J.g of PRL- SV40 Renilla luciferase expression vector
which was co-transfected to normalize the transfection efficiency. Some cells
were also co-transfected with 4 J.g of either MKK3(ala), p38(agf), MKK3(glu) or
MKK6(glu) or empty expression vector. Three hours after transfection , the cells
were harvested and split evenly into two wells. 24 hours later, one group of cells
was left untreated and the other group was incubated with LPS (1 J.g/ml). In
some experiments , the transfected cells were pretreated with SB202190 (2 J.M)
for one hour before LPS treatment. 24 hours after LPS treatment, cell extracts
were prepared and luciferase activity was measured by using the Dual-
Luciferase system (Promega Corp. , Madison, WI).
In vitro T cell differentiation. CD4+ T cells were isolated from spleen and
lymph nodes of six-week old mice by negative selection as described (167 257).
Naive CD4+ T cells were then isolated by sorting for CD4410w CD45RBhigh cells.
APCs were obtained by gamma- irradiation and negative selection (257).
5x105 naive CD4 + T cells were incubated with an equal number of APCs
in Bruff medium with 5% FCS (Life Technologies, Inc. Gaithersburg, MD), 2 mM
glutamine , and penicillin/streptomycin in the presence of Con A (2.5 1l9/ml), IL-
2 (20 U/ml) and anti- IL-4 (Clone 11 B11) with or without IL- 12 (3.5 ng/ml) for 4
days. The cells were exhaustively washed , counted and restimulated at 5x10
cells/ml with Con A (2.5 1l9/ml) for 20 h. The supernatants were collected and
IFN-y production was measured by ELISA.
Measurement and induction of the KLH recall res onse. Mice were
immunized with 50 1l9/ml of KLH in CFA in each of the hind footpads. Draining
lymph nodes were isolated 9 days later. The lymphocytes were cultured in 96-
well plates (5X105 cells/well) in the presence of KLH of different concentrations 
vitro. One group was incubated with 1 IlCi/well 3 thymidine at day 3. At day 4
proliferation was assayed by determining the incorporation of 3 thymidine. The
supernatants of other groups were assayed at day 5 by ELISA for IFN-
production.
Results
Normal develo ment of mkk3 hoc tes. mkk3 /-) mice have normal
numbers of thymocytes and splenocytes. Major cell surface markers of T and B
lymphocytes were examined by flow cytometric analysis of cells derived from
freshly isolated thymus , spleen and lymph nodes. The wild-type and knockout
mice have similar expression of CD3 , CD4 , CD8, CD25, CD44 , CD69, TCR a/B
and Y/b B220, F4/80 and major histocompatibility complex class II antigen I-Ab.
The number of bone marrow-derived dendritic cells (DCs), as well as CD11c , 1-
Ab and B7-2 surface markers also did not differ between DCs from wild-type
(+/+) and mkk3 
/-). 
No obvious defects in lymphocyte development were
therefore evident in mkk3 /-) mice.
Defective 38 MAP kinase activit in mkk3 macro es. By the use 
the chemical inhibitors, the p38 kinase pathway has been implicated in the
regulation of the expression of TNF-a, IL- , IL-6, and GM-CSF (9, 100). Since
many of the inflammatory cytokines are produced by macrophages upon
activation by LPS, a potent activator of the p38 MAP kinase pathway, LPS-
activated p38 MAP kinase activity in mkk3 /-) macrophages was studied. There
was reduced p38 MAP kinase activation in mkk3 
/-) 
macrophages in
comparison to wild-type macrophages (Fig. 4. 1 a); interestingly however, the
activation of p38 MAP kinase in response to sorbitol was similar in the wild-type
and knockout macrophages (Fig. 4. 1 b), indicating that LPS- induced p38 MAP
kinase activation was selectively defective in the MKK3-deficient macrophages.
On the other hand , JNK activity induced by LPS in mkk3 /-) macrophages was
not reduced (Fig 4. 1 a).
In order for MKK3 deficiency to account for the defect in p38 activation in
mkk3 /-) macrophages , it is necessary that LPS activates MKK3. To test this
directly, RAW264.7 macrophages were transfected with an MKK3 expression
vector and activated with LPS. MKK3 was then immunoprecipitated and p38
activity was measured by a coupled kinase assay (Fig. 4. 1c). MKK3-directed
p38 activation was stimulated more than 4 fold by LPS, showing that LPS indeed
activates MKK3.
Defective IL- 12 roduction in mkk3 anti en- resentin cells APCs . To
test whether the expression of inflammatory cytokines was affected in mkk3 
/-)
mice , LPS-stimulated macrophage RNA was isolated and subjected to RNase
protection assay (RPA) by using a panel of inflammatory cytokine probe sets. IL-
6, TNF-a, IL-1a and IL- 1B mRNAs accumulated upon LPS stimulation in the wild-
Figure 4. p38 MAPK activity in mkk3 (-1-) and wild-type primary
macrophages and the macrophage cell line RAW264.
Peritoneal macrophages from wild-type (+/+) and mkk3 /-) mice were left
untreated (control) or treated with (A) LPS (100 ng/ml) or (B) sorbitol (300 mM)
for 5, 15 and 30 min. The p38 MAPK activity was measured using an
immunecomplex kinase assay with the substrate GST-ATF2. (C) RAW264.
cells were transiently transfected with an MKK3 expression vector. 24 hours
later, the cells were left untreated or treated with LPS for 30 min. MKK3 was
immunoprecipitated from the cell Iysates. Kinase assays were performed using
the immunoprecipitates, GST-p38y, GST-ATF2 and y- ATP. The radioactivity
incorporated into GST-ATF2 was quantitated after SDS/PAGE by
Phosphorlmager analysis and presented as relative p38 MAPK activity. The
results shown were obtained in a single experiment and are representative of two
separate experiments with similar results.
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type and the knockout macrophages to a similar degree (Fig. 4.2), indicating that
MKK3 deficiency did not affect the expression of these four cytokine mRNAs.
Both IL- 12 p40 and p35 mRNAs were up regulated in wild-type macro phages,
but unexpectedly, the level of p40 mRNA was barely detectable and p35 mRNA
expression was also greatly reduced in the mkk3 /-) macrophages (Figs. 4.
and c). There was also a small decrease of TGFB2 mRNA in the mkk3 /-) (20%
reduction) (Fig. 4.2b and c). Relative inhibition of cytokine expression in
knockout versus wild-type mice is shown in Fig. 4.2c.
IL- 12 is secreted by antigen-presenting cells (APCs), including
macrophages and dendritic cells, when microbial pathogens are encountered. To
examine the sta.tus of IL- 12 protein production by APCs in mkk3 /-) mice
peritoneal macrophages from both wild-type and knockout mice were activated
with LPS and IL-12 production was measured by ELISA after stimulation. There
was a marked reduction in IL- 12 expressed by the knockout macrophages when
compared to the wild-type macrophages (Fig. 4.3a) consistent with the RPA data.
This LPS- induced production of IL-12 was also inhibited by SB 203580 and SB
202190, two inhibitors of p38 MAP kinase, but not by SB 202474 , a chemical with
similar structure that was used as a negative control (Fig. 4.3a). Together, these
Figure 4. LPS induced inflammatory cytokine mRNA expression is
reduced in mkk(-I-) macrophages
Peritoneal macrophages from wild-type (+/+) and mkk3 /-) mice were left
untreated (control) or treated with LPS for 6 hours. Total RNA was extracted and
subjected to RNAase protection assay (Pharmingen) utilizing the template sets
(A) mCK- 2b or (B) mCK- (C) Protected bands were quantitated by
Phosphorimager analysis using the housekeeping GAPDH as an internal control.
Percent inhibition was calculated by the following formula:
percent inhibition (%) = 100 X ((+/+ cytokine:GAPDH) - (-/- cytokine:GAPDH)) /
(+/+ cytokine:GAPDH).
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data indicate that MKK3-directed p38 activation is required for LPS- induced IL-
production in macrophages.
Dendritic cells, another major APC type , are a key source of IL-12 in
response to stimulation with CD40L in the presence of low amounts of LPS (18,
, 184). Therefore IL-12 production by DCs was also measured. IL-
production was highly induced by CD40L in wild type DCs in a dose-dependent
manner; however, the induction of IL- 12 production by CD40-CD40L
engagement was markedly reduced in the mkk3 /-) DCs (Fig. 4.3b). These
results demonstrate that there was a general impairment of IL-12 production by
mkk3 /-) APC'
The amount of protein secretion of TNF-a and IL- 6 in mkk3 
/-)
macrophages was comparable to that of the wild-type (+/+) macrophages upon
LPS stimulation (Figs. 4.4a and b). Together with the RPA data which showed
litte difference in the amounts of mRNA of these two cytokines between the wild-
type (+/+) and the mkk3 /-) macrophages, these results suggested that MKK3
was not required for the production of IL-6 and TNF-a mRNA in LPS-stimulated
macrophages. In contrast, the secretion of both IL- 1a and IL-1B protein was
reduced in mkk3 /-) macrophages (Fig. 4.4 c and d). This contrasts however
Figure 4.3 Inflammatory cytokine production induced by LPS is reduced in
mkk3 (-1-) mice.
(A). IL- 12 production in wild type (+/+) and mkk3 /-) macrophages. Peritoneal
macrophages were left untreated, treated with LPS (100 ng/ml) for 20 hr, or
pretreated with SB 203580 (10 J.M), SB 202190 (10 J.M) or SB 202474 (10f.M)
for 2 hr before LPS (100 ng/ml) was added for an additional 20 hr. Supernatants
were collected and IL-12 production was measured by ELISA. The mean and
standard error are shown. The results shown in this experiment were
representative of six separate experiments with similar results.
(B). IL- 12 production by CD40-CD40L engagement in bone marrow-derived
dendritic cells. Bone marrow-derived dendritic cells were left untreated or treated
with different concentrations of membrane-bound CD40L (1: 100 and 1 :500) for
48 hr. Supernatants were collected and IL-12 production was measured by
ELISA. The mean and standard error are shown. The results shown in this
experiment were representative of two separate experiments with similar results.
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Figure 4. Reduction in LPS induced IL- 1 production in mkk3 -
macrophages
(A) IL-6 and TNF-a production wild type (+/+) and mkk3 /-) macrophages.
Peritoneal macrophages were left untreated or treated with LPS (100 ng/ml) for
20 hr or pretreated with SB 202190 (10 J.M) for 2 hr before LPS (100 ng/ml) was
added for an additional 20 hr. Supernatants were collected and IL-6 and TNF-a
production were measured by ELISA. The mean and standard error are shown.
The results shown in this experiment were representative of three separate
experiments with similar results.
(B) IL-1a and IL- 1B production in wild type (+/+) and mkk3 /-) macrophages.
Peritoneal macrophages were left untreated or treated with LPS (100 ng/ml) for 4
hr or pretreated with SB 202190 (10 J.M) for 2 hr before LPS (100 ng/ml) was
added for an additional 4 hr. A TP (5 mM) was added to the culture for 30 min to
induce the release of IL- 1 into the supernatant. The supernatants were collected
and IL- 1 (a and B) production was measured by ELISA. The mean and standard
error are shown. The results shown were obtained in a single experiment and are
representative of three separate experiments with similar results.
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with the RPA analysis for IL- 1 a and IL- 1 B mRNA (Fig. 4.2a and c), suggesting
that MKK3-directed p38 MAP kinase might be involved in IL- 1 translational or
post-translational regulation.
ulation of the IL-12 40 romoter b the 38 MAP kinase athwa . To
further study the molecular mechanisms underlying the regulation of IL-12 by the
MKK3-directed p38 MAP kinase pathway, IL-12 p40 reporter gene expression
was examined in macrophages. Since it is very difficult to transfect primary
macrophages, the murine macrophage cell line RAW264.7 was used for these
co-transfection experiments. An I L - 12 p40 reporter construct, containing the
350 to +55 region of the I L - 12 p40 promoter driving a firefly luciferase gene
(156), was transiently transfected into RAW264.7 cells. Luciferase activity was
strongly induced by LPS and was dependent on the p38 MAP kinase pathway
since this induction was blocked by SB202190 (Fig. 4.5a), but not by the control
drug SB202474 This LPS- induced I L- 12 p40 promoter-driven luciferase
expression was also suppressed when a dominant negative expression construct
of MKK3 or p38 MAP kinase was co-transfected (Fig. 4.5a); thus the p38 MAP
kinase pathway is required for LPS- induced IL- 12 p40 reporter expression , acting
at least in part at the transcriptional level. Since the p40 promoter used for these
experiments contains the 5' UTR, these observations do not exclude the
possibility that p38 MAP kinase may also regulate IL-12 p40 expression post-
transcriptionally by acting through the 5' UTR.
To examine which isoform of p38 contributes to the regulation of IL-
expression , activated MKK3 and MKK6, MKK3 (glu) and MKK6 (glu) respectively,
were co-transfected with different p38 isoforms and their ability to activate the
p40 promoter was studied. It appears that MKK3(glu) activates the IL-12 p40
promoter through p38a but less well through p38B, p38y and p38o; while
MKK6(glu) primarily acted through p38a and p38B (Fig. 4.5b). These data
indicated that p38a was directly involved in the regulation of IL- 12 p40
expression.
aired t e I c tokine immune res onse in mkk3 mice. The p38 MAP
kinase pathway is activated upon TCR ligation and T cell activation (167, 171
177). Recently it has been demonstrated that p38 MAP kinase mediates
interferon-y (IFN-y) expression in T helper 1 (T H 1) effector cells (167). IL-12 is an
inflammatory cytokine linking the innate and adaptive immune responses. It
induces the production of IFN-y and is therefore a critical mediator of the
proinflammatory antigen-specific T H 1 , cytotoxic T lymphocyte (CTL) and natural
killer (NK) cell cytotoxic response (1 49, 71 , 151, 168, 231). To determine if IFN-
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Figure 4.5 IL-12 p40 promoter activity is regulated by the p38 MAPK
signaling pathway in RAW264.7 macrophages.
RAW264.7 macrophages were transiently transfected with the IL-12 p40-
Luciferase reporter (A) with or without MKK3(ala) or p38(AGF) or (B) together
with MKK3(glu) or MKK6(glu) with or without p38a, p38B, p38y, or p386
respectively. Transfected cells were spli into two wells and left untreated or
were treated with LPS for 24 hours in the presence or absence of SB202190 .
The luciferase activity was measured by standard techniques.
production was impaired in mkk3 /-) mice , naive CD4 T-cells were differentiated
into T H 1 cells in vitro using standard techniques (42, 167, 168, 257). Sorted
CD4410w CD45RBhigh naive CD4+ T cells were cultured with APCs in the
presence of Concanavalin-A (Con-A), interleukin-2 (IL-2), and anti- IL-4 antibody
for 4 days. After extensive washing, the cells were replated and cultured for
another day in the presence of Con A. IFN-y production was then measured.
Wild-type T cells incubated with wild-type APC produce large amounts of IFN-
whereas knockout T cells incubated with knockout APC produced litte IFN-y(Fig.
6), indicating that IFN-y production was impaired in mkk3 /-) mice. To test
whether this defect resulted from an intrinsic deficiency in the property of T 
H 1
CD4+ T cells with reduced p38 activity that was described previously (167), or
also from an APC deficiency, as described here resulting from impaired IL-
production , wild-type naive CD4+ T cells were incubated with knockout APCs
and similarly, knockout naive CD4+ cells were incubated with wild-type APCs
under the same conditions. In both cases, IFN-y production was greatly reduced
compared to that of the wild-type T cells and APC, but was still substantially
higher than that of knockout T cells plus knockout APC (Fig. 4.6). This result
suggested that both knockout T cells and knockout APCs were intrinsically
defective, and that both contribute to the diminished production of IFN-y in the
knockout mice.
Figure 4.6 IFN-y production after in vitro differentiation of naive CD4+ T
cells.
Sorted CD4410wCD45RBhigh naive CD4+ cells from wild-type (T +) and
MKK3-deficient mice (T-) were cultured with either the wild-type APCs (APC+) or
knockout APCs (APC-) in the presence of Con A, IL-2 and anti- IL-4 antibody for 4
days. The cells were then washed extensively and re-stimulated with Con A for
another day. IFN-y production in the supernatants was measured by ELISA. The
mean and standard error are shown. The results shown in this experiment were
representative of three separate experiments with similar outcomes.
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To further examine whether T H 1 CD4+ T cell responses were defective in the
mkk3 /-) mice in vivo the KLH recall response was examined by measuring
IFN-y secretion from lymphocytes after secondary antigenic challenge ex vivo.
Wild type (+/+) mice exhibited dose-dependent increase in IFN-y production in
response to KLH. In contrast mkk3 /-) littermates produced little IFN-y during
re-stimulation with KLH (Fig. 4.7a). To rule out the possibility that this was due to
unresponsiveness of mkk3 /-) lymphocytes to KLH , T cell proliferation was
examined by 3 thymidine incorporation assays. Wild type (+/+) and mkk3 
/-)
T-cells incorporated similar amounts of 3 thymidine in response to KLH
restimulation. (Fig. 4.7b). Thus the ability to secrete IFN-y in response to antigens
was therefore greatly impaired , but not completely absent , in mkk3 /-) mice.
Figure 4.7 KLH- induced IFN-y production is reduced in mkk3 (-1-) mice.
(A) IFN-y production induced by KLH. Mice were immunized with Keyhole limpet
hemocyanin (KLH) in complete Freund' s adjuvant (CFA) in the footpads. Nine
days later, lymphocytes from the draining lymph nodes in the treated mice were
isolated and incubated in vitro with different concentrations of KLH for 4 days.
The supernatants were collected and ELISA was performed to examine the
induction of IFN-y in the supernatants. The mean and standard error are shown.
The results obtained in this experiment were representative of two separate
experiments with similar results. b. Proliferation of lymphocytes in response to
KLH in vitro. Lymphocytes isolated from draining lymph nodes after nine days of
initial challenge with KLH-CFA were incubated in vitro with different
concentrations of KLH. At day 3, (3H)thymidine was added to the culture media.
The proliferation response was measured at day 4 by examining the
incorporation of (3H)thymidine. The mean and standard error are shown. The
results shown in this experiment were representative of two separate
experiments with similar results.
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Discussion
Mice with a targeted disruption of the mkk3 gene were generated and
shown to have fundamental defects in the inflammatory response and the T H 1
CD4+ T cell response. Three upstream kinases that activate p38 MAP kinase
have been reported: MKK3, MKK4 and MKK6 (227). MKK4 activates JNK and
p38 MAP kinase in vitro (31 , 104), however, there was no defect in p38 MAP
kinase activation in MKK4-deficient embryonic stem (ES) cells although p38 MAP
kinase activation in Mkk4 /-) MEF was reduced (46 , 149, 241). At present, MKK3
and MKK6 are the only known specific p38 MAP kinase activators. By using
transient transfection of genes encoding MKK3 or MKK6 and other biochemical
characterization in vitro, many reports suggested that MKK6 is the most potent
activator of p38 MAP kinase (25 , 133, 162). The relative contribution of MKK3
versus MKK6 in vivo is, however , undefined; the generation of mkk3 /-) mice
therefore provides an opportunity to determine the role of MKK3 versus MKK6 
vivo. LPS-activated p38 MAP kinase activity was reduced, but not absent, in
mkk3 /-) macrophages (Fig. 4. 1a). On the other hand , p38 MAP kinase activity
induced by sorbitol in MKK3-deficient macrophages was intact suggesting that
MKK3 was required for full activation of p38 MAP kinase by LPS (Fig. 4. 1 b). The
biological significance of this LPS- induced p38 MAP kinase defect in mkk3 
/-)
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mice was illustrated by the demonstration that LPS- induced IL- 12 production and
IL-12 p40 mRNA expression by macrophages was almost completely blocked in
mkk3 /-) mice (Figs. 4.2 and 4.3).
Bacterial LPS is one of the most potent activators of cells of the monocyte
lineage. LPS forms a complex with the serum protein LPS-binding protein (LBP),
the LPS-LBP complex then binds to CD14 on the cell surface to induce a signal
within the cell , probably through a Toll-like receptor (89, 157, 211 , 244). LPS has
been shown to induce activation of all three MAPK pathways including ERK , JNK
and p38, in addition to PKC, ceramide and PKA; however, the significance of
each pathway in connecting LPS to intracellular gene activation is unknown
(195). It has been shown that the p38 MAP kinase pathway is involved in the
LPS- induced biosynthesis of TNF-a, IL- 1, IL-6 and GM-CSF (9, 100) and that the
JNK and ERK pathways are also involved in TNF-a production induced by LPS
(194 , 255). mkk3 /-) mice have enabled us to study the contribution of the
MKK3-directed p38 MAP kinase pathway to the regulation of LPS- induced
cytokine production in macrophages. Secretion of IL-6 and TNF-a by peritoneal
macrophages in response to LPS stimulation in vitro revealed little defect, if any,
in the mkk3 /-) mice , suggesting that MKK3 is not required for these processes.
The biosynthesis of IL-6 and TNF-a was partially inhibited by the p38 MAP
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kinase inhibitor SB 202190 (Figs. 4.4a and b). Thus , there is an SB 202190-
sensitive pathway that contributes to IL-6 and TNF-a production that is not
MKK3-dependent; presumably MKK6 may compensate for the MKK3 defect , or
be wholly responsible for the induction of these cytokines. On the other hand, IL-
1a and IL- 1B production (but not mRNA expression) was reduced in mkk3 
/-)
(Figs. 4.4c and d), indicative of a role of the MKK3-directed p38 MAP kinase
pathway in the production of IL- 1a and IL- 1B that acts at the translational or post-
translational level, as suggested previously (l00). The most dramatic effect
observed in mkk3 /-) mice , however, was the almost complete absence of IL-
production caused by LPS in macrophages and by CD40-CD40L interactions in
dendritic cells (Fig. 4.3 a-b). This was surprising, because IL- 12 biosynthesis had
not been previously known to be regulated by the p38 MAP kinase pathway.
Interleukin- 12 is a heterodimeric cytokine that consists of p35 and p40
subunits. It plays a central role in driving naive CD4 T cells into differentiated T H 1
cells by inducing the production of IFN-y, an important effector in both adaptive
cellular immunity and innate immunity (48, 208). Among its many
immunomodulatory effects in both innate and adaptive immunity, IFN-y up-
regulates major histocompatibility complex (MHC) class I and II antigen
expression, stimulates specific CD8 T cell-mediated cytotoxic immunity through
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recognition of specific MHC class I and antigen complexes, and enhances innate
immunity by activation of macrophages and NK cells (11, 209). IL- 12 therefore
serves as a bridge connecting innate immunity to adaptive immunity (209). IL-
is secreted mainly by APCs upon innate immune recognition of pathogen-
associated molecular patterns including LPS (119). However, the signaling
pathway leading to IL-12 production was hitherto undefined (151). The p38 MAP
kinase pathway was induced by LPS and peptidoglycan , the major molecular
recognition pattern among Gram-negative and Gram-positive bacteria,
respectively (35 , 59). This suggested that the p38 MAP kinase pathway is
activated during the innate immune recognition process. It is particularly
satisfying therefore that one of the downstream targets of the p38 MAP kinase
pathway is IL-12, which , upon induction by microbial products via the p38 MAP
kinase pathway, would initiate antigen-specific adaptive immunity. The type I
immune response to the protein antigen KLH (in CFA), an adjuvant which favors
T H 1 responses through the production of IL- 12 (43), was compromised in mkk3 
/-) mice (Fig. 4.7a). IFN-y production by differentiated CD4+ T cells was also
greatly reduced in mkk3 /-) mice. Intrinsic defects in both mkk3 
/-) T-cells and
APC contributed to this impairment (Fig. 4.6). The APC defect was likely caused
by the impairment of IL-12 production since mice deficient for IL- 12-p40, IL-
receptor beta1 and Stat 4, a signaling molecule that is required for IL-
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responsiveness , also exhibit defective type I cytokine immune responses (84
112, 204, 234). Taken together, these results suggest that MKK3 plays a
determining role in driving downstream p38 MAP kinase activation to regulate IL-
12 production in APC.
Analysis of mRNA demonstrated that IL- 12 p40 gene expression was
almost absent in the mkk3 /-) mice (Fig. 4.2a and c); IL- 12 p35 mRNA level was
also reduced (Fig. 4.2a and 4.2c). Likewise, p40 promoter-driven reporter
expression was blocked by SB202190 and dominant negative expression
constructs for MKK3 and p38 MAP kinase (Fig. 4.5a). These results indicated
that p38 MAP kinase regulates IL-12 p40 transcriptionally, at least in part. In
comparison to the IL-12 p35 promoter, the IL- 12 p40 promoter and the
transcription factors that bind to it are better characterized. C/EBP and NF-
family members together with an ets-2-related factor have been shown to bind to
their corresponding sites in the p40 promoter and regulate the expression of this
gene (56, 110 , 111 , 140, 156). By the use of gene disruptions in mice , IRF- 1 and
ICSBP , another member of the IRF- 1 family, have been shown to be required for
IL-12 p40 expression (51 , 106, 172, 199). Since many of the identified substrates
for p38 MAP kinase are transcription factors, and furthermore, since the p38
MAP kinase pathway can contribute to NF-KB-mediated transactivation (9, 212), it
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is tempting to speculate that the p38 MAP kinase pathway may regulate IL-
p40 transcription by regulating the activity of either IRF-1 family members,
C/EBP, NF-kB or the ets-2-related factor, directly or indirectly. Further work will
be required to test this hypothesis. It was also possible that the inhibition of IL-
production in mkk3 /-) mice was mediated by IL-10, IL- , or TGF-B, cytokines
that suppress the production of IL-12 (181). This was considered unlikely since a
reduction rather than an increase of TGFB2 production in mkk3 
/-)
macrophages was demonstrated using a sensitive RNase protection assay (Fig.
2b and c), and because the production of IL-4 and IL-10 mRNA response to
antigen was similar in wild-type (+/+) and mkk3 /-) T cells). It was also
observed that LPS- induced IL-12 production was inhibited by SB 203580 and SB
202190 (Fig. 4a). Since p38a and p38B are inhibited by these drugs , the LPS-
induced, MKK3-directed IL-12 production was likely mediated , in part, by the
activation of p38a. This conclusion was supported by the observation that p38a
potentiates the transactivation of an IL- 12 p40 luciferase reporter mediated by
constitutive active MKK3a in RAW264.7 macrophages (Fig. 4.5b).
., An interesting parallel can be drawn between the role of the p38 MAP
kinase pathway in inflammatory APC, such as macrophages and DC, and its role
in T cells. The production of IL- 12 in APC and the production of IFN-y in T cells
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all require the p38 MAP kinase pathway, shown by us here and elsewhere (167).
The ancient p38 MAP kinase pathway appears to have been used repeatedly
during evolution for a variety of stress responses, ranging from osmotic stress in
single-cell organisms like yeast (67), regulation of antimicrobial peptide
expression in insects(63), to the production of inflammatory cytokines by
fibroblasts (236) macrophages and dendritic cells in the innate immune response
and finally in the proinflammatory T H 1 adaptive immune response (167)(this
study) developed in higher vertebrates. The conservation of function was unlikely
to be fortuitous and may be repeated for other signaling pathways.
'''
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CHAPTER V.
CONCLUSIONS
Structure of the mkk3 ene. Molecular cloning studies have led to the
identification of two isoforms of MKK3 in humans (MKK3a and b) that differ by 29
amino acids in the NH terminal region (31 , 133). However, analysis of mRNA
and protein expression in mouse tissues identified only the MKK3b isoform (31
, 133) (Fig 3. 1 d). Analysis of the S' terminal region of the human mkk3 gene
revealed that it encodes both MKK3a and MKK3b (Fig. 1 a). In contrast , the
murine mkk3 gene encodes a single MKK3 isoform , MKK3b (Fig. 2. 1). The S'
UTR of human MKK3a is encoded by three exons unique to MKK3a and one
exon that is shared by MKK3a and MKK3b. Alignment of human MKK3a and
MKK3b cDNA sequences demonstrates that the S' UTR' s are distinct. These
observations suggest that MKK3a and MKK3b are expressed from different
promoters in humans and that MKK3b may be the sole murine isoform.
ulation of MKK3 ex ression. MKK3 mRNA is ubiquitously expressed and
is enriched in skeletal muscle (31 61). Characterization of the murine mkk3 gene
reveals a potential mechanism for maintaining robust expression of MKK3b
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mRNA in skeletal muscle. The murine mkk35' flanking region contains multiple
cis-acting sequence elements encoding binding sites for the transcription factors
MyoD and MEF2. Transient transfection studies demonstrated that murine mkk3
expression was stimulated by MyoD and E12 during in vitro myogenic conversion
of 10T1/2 fibroblasts (Fig. 2.5a). MyoD stimulated MKK3b expression was
enhanced by activation of the p38 MAP kinase signaling pathway (Fig. 2. 6a). In
contrast , activation of the Erk5 signaling pathway had no effect on mkk3
expression (Fig 2.6b). This effect could be mediated by the transcription factors
MEF2A or MEF2C, both of which are targets of the p38 MAP kinase signaling
pathway and cooperate with MyoD to mediate muscle specific gene expression
(245 , 254 , 256). However, MEF2C does not activate expression of an mkk3
reporter plasmid (Fig. 2.6, Fig 2.8).
Expression of MKK6 (glu) activates MyoD-dependent mkk3-reporter
expression independent of MEF2C coexpression in 1 OT1/2 fibroblasts (Fig. 2.8).
Thus , p38 MAP kinase signaling pathway may activate MyoD-dependent gene
expression in the absence of MEF2 (160, 235). It is also possible that MEF2
proteins are important in other cellular contexts. For example , MEF2C has been
shown to regulate gene expression in macrophages , T -cells and primary cortical
neurons (58 , 93). MEF2C is also activated by LPS in the macrophage cell line
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RAW 264.7 resulting in increased transcription of c-Jun (58). Thus MEF2C may
regulate expression of mkk3 in a similar manner. Further studies are required to
test the hypothesis that MKK3 expression is regulated my MEF2 
macrophages.
Fibroblasts. Targeted disruption of the mkk3 gene was predicted to cause
defects in the p38 MAP kinase signaling pathway. The mkk3 /-) mice were
viable and fertile with no observed developmental defects. Primary embryo
fibroblasts (MEF) derived from wild type and mkk3 /-) embryos were therefore
used to examine regulation of the p38 MAP kinase signaling pathway I found a
specific defect in the response of mkk3 /-) MEF to the inflammatory cytokine
TNF-a. This results in diminished expression and production of IL-6 and IL- 1 by
TNF-a treated MEF. In addition, there are defects in TNF-a-induced
accumulation of MIP1 a, IB and 2 mRNA in mkk3 /-) MEF (Fig 3.5). In contrast,
accumulation of IL- 1 RA (Fig3.4b) and RANTES mRNA (Fig. 3.5) are increased
by mkk3 
/-) 
MEF. As its name suggests IL- 1 RA dampens the inflammatory
response by acting an antagonist for the type 1 IL-1 receptor. These data
demonstrate that MKK3 is a critical mediator of signaling from cytokine receptors
to the p38 MAP kinase pathway in fibroblasts. They also suggest that the p38
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MAP kinase signaling modulates the inflammatory response by suppressing IL-
1 RA and RANTES expression.
Chemokines are soluble inflammatory mediators with molecular weights in
the 8- to 20 kd range (with few exceptions) (169). There are two major
chemokine sub-groups called CXC and CC. The B-chemokines belong in the CC
sub-group because of the arrangement of two conserved cysteines in the NH2
terminal region (169). There are seven chemokine receptors that selectively
interact with B-chemokines: RANTES interacts with the CC chemokine receptors
(CCR) CCR1 , CCR3, CCR4 and CCRS; MIP1a interacts with CCR1, CCR4 and
CCRS; and MIP1 B interacts with CCRS (reviewed in (169)). Targeted disruption
studies demonstrated that CCR1, CCR2 , and CCRS modulate T H 1 and T H
responses (4, 12 96). Examination of ccr1 /-) mice revealed a diminished
T H2 response, decreased IL-4 production and increased IFN-y production (47).
In contrast, ccr2 /-) and ccr5 /-) mice exhibit diminished IL-12 and IFN-
production consistent with a T H 1 defect (4, 12 96). CCRS positively regulates IL-
12 production by CD8a + dendritic cells in response to microbial pathogens and
RANTES, MIP1 a, and 1 B (4). The observations that mkk3 
/-) 
MEF exhibit
reductions in MIP1 a, 1 Band 2 expression and increased RANTES expression
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suggest that the p38 signaling pathway may modulate the immune response by
regulating fibroblast expression of B-chemokines.
Until recently, fibroblasts have been considered structural cells that
provide scaffolding on which other cells function and migrate (183). It has
become apparent that fibroblasts are important mediators of the immune
response through the regulated biosynthesis of cytokines and chemokines.
Assuming that fibroblasts contribute to the T H 1 versus T H2 decision and that
MEF are representative of fibroblasts in general then there is evidence linking
cytokine secretion by fibroblasts to the T H 1 inflammatory response. The inabiliy
of mkk3 /-) fibroblasts to express MIP1a, 1B and 2could help explain the
diminished T H 1 response of mkk3 /-) mice (see below).
Macro es. Targeted disruption of the mkk3 gene was also predicted to
cause defects in the p38 MAP kinase pathway in macrophages. LPS activation
of p38 MAP kinase was greatly diminished in mkk3 /-) macrophages (Fig. 4. 1).
LPS-stimulated IL-1a and B production by mkk3 /-) macrophages was also
diminished (Fig. 4.4c-d). The studies presented here also demonstrated that
LPS induced TNF-a and IL-6 production was comparable between mkk3 /-) and
wild-type (+/+) macrophages (Fig. 4.4a). In addition , LPS stimulated TNF-a
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accumulation was modestly reduced by SB203580 (Fig 4.4a). These
observations suggest that TNF-a expression is regulated by an MKK3-
independent signaling pathway in macrophages. Alternatively, the low level of
p38a activity observed in mkk3 /-) macrophages may be sufficient to support
TNF-a expression.
The most profound phenotype observed in the mkk3 /-) mice was the
almost complete lack of LPS-stimulated IL-12 production by macrophages. (Fig.
3a). Pretreatment of macrophages with SB203680 also dramatically
diminished LPS-stimulated IL-12 production (Fig 4.3a). These observations
suggest that LPS induced IL- 12 biosynthesis is regulated by a p38a dependent
pathway, although contributions by p38B cannot be eliminated. This is 
agreement with transient transfection studies in the macrophage cell line RAW
264.7 in which MKK3 and MKK6 both stimulate expression of an IL- 12 p40
promoter luciferase reporter construct, primarily through p38a (Fig. 4.5b). LPS
also activates ectopically expressed MKK3 and MKK6 in RAW 264.7 cells (Fig.
1 b). Thus, MKK3 and MKK6 are likely equally required for p38 activation by
LPS in macrophages.
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T H 1 inflammator res onse. The decision to mount a T H 1 or T H2 response is
made largely as a result of the local cytokine environment at the site of insult or
injury. This is partly due to cytokines secreted by APC, particularly macrophages
and dendritic cells. Previous observations have strongly implicated the
inflammatory cytokine , IL- , as an important mediator of the T H 1 response (48
208 , 209). The p38 MAP kinase pathway has also been implicated in the
developmental switch to a T H 1 immune response, primarily through the
regulation of IFN-y expression (167). The observation that MKK3-deficient
macro phages and dendritic cells exhibit defects in IL- 12 biosynthesis predicts
that mkk3 /-) mice would have a defect in the T H 1-specific immune response
(Fig. 4.3a-b). This in fact what was observed during in vivo and in vitro
development of mkk3 /-) T H 1 cells (Figs. 4. 6, 4.7). These data describe a direct
link between the activation of the p38 MAP kinase pathway and stimulation of IL-
12 production resulting in development of a T H 1 response and IFN-y production.
Thus, the p38 MAP kinase pathway is critical for the proper execution of a T H 1
response including regulating T H 1-specific cytokine production (108 , 167).
Another cytokine implicated in mediating T-cell responses, IL-6, is
secreted by antigen presenting cells and polarizes naive CD4+ T-cells into T H
cells through stimulation of IL-4 expression (166). There was little difference in
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LPS stimulated IL- 6 production between mkk3 /-) and wild type 
(+/+)
macrophages (Fig 4.4) In addition IL-6 biosynthesis was not significantly affected
by pre-treatment with SB203580 suggesting that IL-6 production is regulated by a
mechanism distinct from IL-12. During development of a T cell response , p38
MAP kinase is selectively activated in T H 1 cells with litte activation seen in T H
cells (167). Mkk3 /-) mice exhibited diminished IFN-y secretion by APC and T-
cells consistent with a T H 1 specific defect (Figs. 4. 6, 4.
Although these studies create a sound basis for understanding the relative
contribution of MKK3 to p38 MAP kinase signaling, some fundamental questions
remain to be addressed. It is still unclear how specificity is maintained in the p38
MAP kinase pathway. There are recent reports of stimuli that selectively activate
a subset of p38 MAP kinases. This selectivity could be due to differential
expression of MAP kinases and MAP kinase kinases in the tissues tested. 
cardiomyocytes, for instance, expression of various combinations of MKK3 and
MKK6 with p38a and p38B have different effects on the expression of
hypertrophic genes versus apoptotic genes (216). There are also examples of
selective activation of p38 isoforms, MKK3 and MKK6 in natural kiler (NK) cells
and neutrophils. For example a2/Bl integrin ligation on human peripheral blood
natural kiler (NK) cells activated a Rac/MKK3/p38 MAP kinase pathway resulting
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in stimulation of IL-8 production (113). Ligation of a2/B1- integrin induces tyrosine
phosphorylation of the guanine nucleotide exchange factor (GEF) p95-VAV by an
unidentified tyrosine kinase (113). V A V in turn activates the small GTP binding
protein , Rac, by catalyzing GTP for GDP exchange (113). Activated Rac
stimulates the kinase activity of the Ste20-related protein kinase , PAK , which
then activates the dual speicficity MAP kinase kinase MKK3 through an
unknown MAPKKK (113). MKK3 activates a SB203580 sensitive p38 MAP
kinase isoform (either p38a or p38B) stimulating IL-8 production (113). In these
same cells , a2B1- integrin ligation activates the FAK-related non-receptor tyrosine
kinase, Pyk2 resulting in paxillin phosphorylation , elevation of intracellular
calcium and activation of NK cytotoxic functions (52). Human neutrophils
selectively express p38a and p388 without expressing detectable levels of p38B
or p38y (57). LPS selectively activates p38a and this activation was attenuated
by expression of a dominant negative mutant of MKK3 (146 , 147). Expression of
dominant negative MKK6 however has no effect on LPS activation of p38a in
human neutrophils (146, 147). These data suggest that MKK3 and MKK6 are not
functionally redundant in their activation of the p38 MAP kinase pathway.
Inde d, the phenotypes of the mkk3 /-) mouse are consistent with this
conclusion. Similar experiments performed with p38 
/-), 
mkk3 
/-), 
mkk6 
/-)
and mkk3/6 /-) may be useful to examine MKK3 function in the immune system.
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Concluding remarks
The p38 MAP kinase pathway is regulated by multiple inputs and is
specifically activated by two MAP kinase kinases, MKK3 and MKK6 (31 , 60 , 133
162, 186). The p38 MAP kinase signaling pathway is also activated by MKK4 
vitro but the significance of this observation remains unclear (31 38). Focusing
on a single p38 MAP kinase activator allows biochemical studies in particular
model systems to be applied to understanding the role of MKK3 in activating the
p38 MAP kinase signaling pathway. Examination of mkk3 
/-) 
mice
demonstrated the importance of MKK3 for activating p38 MAP kinase pathway in
response to TNF , LPS and during a T H 1 immune response. The challenge now
is to integrate these findings with observations from mice with targeted
disruptions in other genes involved in the p38 MAP kinase signaling pathway
including: mkk6; p38a; p38B; p38y; and p38b; as well as downstream targets of
p38 MAP kinase such as: MAPKAPK-2; PRAK; and others.
There are several protein kinases that are phosphorylated and activated
by p38 MAP kinase including MNK1, MNK2, MAPKAPK2 , MAPKAPK3, MSK1.,
and PRAK (44, 45 , 109, 118, 144, 170, 218). Activation of one of these,
MAPKAPKK2 (MK2), is inhibited by SB203580 indicating that it lies downstream
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of p38a or p38B (97 , 201). Mk2 /-) mice, much like mkk3 /-) mice , are
phenotypically normal by several criteria (92). However mk2 /-) mice have an
inflammatory defect similar to that observed in mkk3 /-) mice. There are also
defects in TNF-a and IFN-y biosynthesis from spleen cells of mk2 /-) mice
injected with LPS (92). These assays, although different from those preformed in
the mkk3 /-) mice, point to a T H 1 defect in the mk2 /-) mice. More modest
defects are observed in biosynthesis of IL-6 and IL- 1 B by cultured mk2 
/-)
spleen cells (92). It is an interesting hypothesis that the p38 signaling pathway
may modulate inflammatory cytokine expression by activating MAPKAPK-
vivo.
The p38 MAP kinase pathway is also important for normal embryonic
development. A targeted disruption of the p38a gene results in early embryonic
lethality in mice. (3 , 5, 139, 200). However, the exact contribution of p38a to
mouse development is controversial (3, 5 , 76, 139, 200). Embyonic lethality has
been attributed to a placental defect in p38a /-) mice (3 , 139). In addition p38a
/-) embryos had significant heart wall defects associated with a reduction in the
myogardial cell population (3) The heart wall abnormality may be secondary to
the placental defect because no significant differences were observed between
wild type and p38a /-) cardiomyocytes (3). Embryonic lethality was rescued by
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tetraploid fusion of a wild type embryo to a p38a /-) embryo resulting in viable
and outwardly normal p38a /-) embryos that survive to term (3). These studies
suggest that the p38 MAP kinase signaling pathway is essential for normal
placenta morphogenesis but may be dispensable for the development of other
organ systems. Studies of mice with targeted disruption of other p38 MAP
kinase isoforms are necessary to test this hypothesis.
Mice with a targeted disruption of the mkk6 gene in a wild type and mkk3
/-) background will be useful to better elaborate the relative roles of MKK3 and
MKK6. Mkk6 /-) mice may have a phenotype similar to the mkk3 /-) mouse.
This result would argue that MKK3 and MKK6 are equally required for activation
of the p38 MAP kinase. Thus it would be necessary to examine the effect of
mkk3/6 double knockout on activation of p38 MAP kinase pathway. A prediction
can be made that the mkk3/6 double knockout mouse will be early embryonic
lethal. This is based on the observation that the p38a knockout mice become
non-viable in utero after approximately day 12 post-coitum (3, 5, 139, 200).
However, p38awas also activated by MKK4 in vitro (31). Targeted disruption of
the rhkk4 gene is also early embryonic lethal (before gestation day 14 post-
coitum) and was associated with abnormal hepatogenesis and hemorrhage (46
241). In contrast, the jnk1/jnk2 embryos die between gestation days 11 and 12
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from a hindbrain neural tube defect with no observed abnormalities in cranial
mesenchyme , yolk sac, embryonic body wall , developing fetal heart or liver (95).
It is possible that early embryonic lethality of the mkk4 /-) mouse may be due, in
part , to reduced p38a activity during development.
It is apparent that MAP kinase signaling pathways are interconnected with
other signaling pathways and are subject to multiple positive and negative
feedback mechanisms. Targeted disruption of the mkk3, jnk1 and jnk2 genes
demonstrate cooperativity between the JNK and p38 MAP kinase pathways.
Mice with null alleles for these three genes have defective T H 1 immune
responses (34, 108 , 242). The JNK signaling pathway regulates the
developmental switch between a T H 1 and T H2 response. In the absence of
JNK1 there was a defect in the down-regulation of T H2 cytokine expression in
T H 1 cells. This was due , in part, to the inability of jnk1 /-) cells to inhibit the
nuclear accumulation of the transcription factor NFATc resulting in diminished IL-
4 expression (34). In contrast , JNK2-deficiency results in a diminished T H
response due primarily to the inability of IL- 12 to upregulate IFN-yexpression.
The conclusion from these observations is that the JNK and p38 stress-
activated protein kinase pathways cooperate in the execution of a T H 1
inflammatory response. This occurs, in part, by inhibition of the T H2-specific
120
transcription factor, NFATc, by increasing the expression of T H 1 specific
cytokines and cytokine receptors (34 , 242).
Despite considerable progress there is still uncertainty regarding the
biological function of the p38 MAP kinase pathway in vivo. The studies
presented here demonstrated that MKK3 has a critical , nonredundant role for
mediating activation of the p38 MAP kinase signaling pathway in response to
inflammatory cytokines, LPS and during a T H 1 immune response. MKK3 specific
signaling may be controlled , in part , by regulated expression or by differential
interaction of MKK3 isoforms with upstream signaling pathways. Further studies
are needed to test these hypotheses.
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